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Introduction
Since the previous version of the European Code Against Cancer
was created [1], the European Union has expanded its number
of Member States and next year (in 2004) will see a further and
dramatic expansion as 10 new Member States join (Cyprus, Czech
Republic, Hungary, Estonia, Malta, Latvia, Lithuania, Poland,
Slovenia and Slovakia). Additionally, it is currently anticipated
that Bulgaria and Romania will be admitted in 2007 followed at a
later date by Turkey. These expansions enlarge the Union to incor-
porate a greater diversity of peoples with a much larger degree of
heterogeneity present in lifestyle habits and disease risk than pre-
viously present. The contrast between the Mediterranean coun-
tries, the Nordic countries and those countries of Central and
Eastern Europe is considerable. In view of the accession of new
States, an important aspect of the revision of this Code was to take
into consideration the specific situation in new Member States.
For the purposes of this text, the European Union shall be defined
as the 15 current Member States (Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Ireland, Italy, Luxembourg,
The Netherlands, Portugal, Spain, Sweden and the UK) plus the
10 Accession Countries scheduled for entry in 2004 (Cyprus,
Czech Republic, Hungary, Estonia, Malta, Latvia, Lithuania,
Poland, Slovenia and Slovakia).
European Union cancer burden
In the European Union in 2000, it is estimated that there were
1892000 incident cases of all forms of cancer (excluding non-
melanoma skin cancers) diagnosed (Table 1): this burden was
shared almost equally by each gender, although there was a slight
excess in men (1014000 cases) over women (878000 cases).
In 2000, it is estimated that there were 1156000 deaths in the
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European Union where cancer was the underlying cause. Of these,
651000 were of men and 504 000 women (Table 1).
The commonest form of cancer diagnosed in the European
Union in 2000 was colorectal cancer, with an estimated total of
258000 new cases. Of these, 123000 were diagnosed in men
while 135000 were in women (Table 2). There was a total of
138000 deaths caused by colorectal cancer in the European Union,
of which 70000 were of men and 68000 women (Table 2).
In 2000, it is estimated that there were 241000 incident cases of
lung cancer, with the majority diagnosed in men (192000 cases)
and fewer in women (49000 cases) (Table 3). In the same year, it
is estimated that there were 231000 deaths in the European Union
caused by lung cancer. Of these, 183000 occurred in men and
49000 in women.
There was an estimated 95500 incident cases of stomach cancer
diagnosed in 2000, of which 57000 were diagnosed in men and
38000 in women (Table 4). There was an estimated total of 78000
deaths caused by stomach cancer: 45000 in men and 32500 in
women (Table 4).
In women, there was an estimated 244500 new cases of breast
cancer diagnosed in the year 2000 and there were 91000 deaths
caused by breast cancer (Table 5). In men, there was an estimated
total of 157000 incident cases of prostate cancer diagnosed in the
European Union in 2000 and an estimated 66500 deaths caused by
this disease (Table 5).
The age-adjusted risk of cancer increases quite quickly with age
[2]: there is a difference of at least two orders of magnitude
between the risk of developing cancer in the fourth decade of life
and the eighth decade of life. Even if age-specific cancer rates
remain fixed at 1980 levels, it is to be expected that there will be
large increases in the numbers of cases of cancer diagnosed for
the first two decades of the twenty-first century. This is simply
a consequence of the ageing population; more and more men
and women living to older and older ages. The postworld war II
‘baby-boom’, the first generation in Western Europe to have had
the benefit of modern medicine and not to have endured a major
war, will reach ages where cancer is an important problem from
the early days of this century. The effect on the absolute numbers
of cases will be quite dramatic, particularly for cancer sites, such
as prostate cancer, where the median age at diagnosis is currently
∼75 years, in the European Union [3].
Cancer control
The diseases grouped under the title ‘cancer’ are remarkably common
and of major public health importance since more than half the
people who develop cancer die from their disease. Thus, the con-
cept of ‘cancer control’ has been developed to attack the cancer
problem at various points in its evolution, with the overall goal of
reducing cancer related suffering and death.
Primary prevention. The most obvious ways to prevent people
dying from cancer are either to find cures for the different forms of
the disease, or to find ways to stop the development of clinical
cancer in the first instance. At the present time, cancer prevention
involves determining the causes of cancer (risk determinants)
from among those factors shown to be associated with the
Table 1. Estimates of numbers of incidence cases and cancer deaths from 
all forms of cancer combined in men and women in Europe, 2000
All but skin cancer estimates for 2000.
EU, European Union; EEA, European Economic Area; APP, accession 
states; WAI, waiting list.
Source: Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: 
Cancer incidence, mortality and prevalence worldwide, Version 1.0. 
IARC CancerBases No. 5. Lyon, France: International Agency for 
Research on Cancer 2001.
Country Men Women
Cases Deaths Cases Deaths
EU Austria 16161 10 105 15495 9470
Belgium 26468 16 697 21480 12 151
Denmark 11 364 8013 13 277 7531
Finland 9841 5700 9986 4958
France 149004 92 541 108132 59 296
Germany 201944 118899 184649 107 213
Greece 21045 14 782 15354 9171
Ireland 6388 4086 6102 3621
Italy 141738 91 397 119 029 65 021
Luxembourg 962 605 853 471
The 
Netherlands
34119 21 425 31852 17 296
Portugal 19611 11 902 16488 8706
Spain 84736 57 800 58699 34 963
Sweden 20653 11 626 20227 10 250
UK 123791 84 722 123876 76 923
EU 867825 550300 745499 427 041
EEA Iceland 496 252 471 257
Norway 9870 5672 9285 4886
Switzerland 15675 9822 13258 7479
EEA 26041 15 746 23014 12 622
EU + EEA EU + EEA 893866 566046 768513 439 663
APP Cyprus 1135 775 862 488
Czech Republic 23582 15 856 21572 12 465
Estonia 2482 1741 2422 1432
Hungary 27683 18 948 24780 14 704
Latvia 3452 2796 3889 2482
Lithuania 5645 4300 5384 3265
Malta 626 426 617 328
Poland 68165 47 101 61391 35 163
Slovakia 9835 6775 8141 4670
Slovenia 3910 2774 3683 2232
Accession 
states
146515 101492 132741 77 229
WAI Bulgaria 14122 9490 12213 6793
Romania 32817 22 383 29984 15 977
Turkey 40976 30 560 26240 15 566
Waiting list 87915 62 433 68437 38 336
Other Albania 3575 2192 2911 1371
Bosnia 
Herzegovina
6078 3745 5377 2607
Croatia 10201 7499 8383 4720
Macedonia 2449 1683 2039 1143
Yugoslavia 17903 10 146 15742 7551
Balkans 40206 25 265 34452 17 392
Eastern Belarus 16854 11 603 13256 7813
Moldova 5250 3465 5181 2639
Russian 
Federation
240809 170132 229475 131 573
Ukraine 83332 57 797 77655 42 816
Eastern 
countries
346245 242997 325567 184 841
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Table 2. Estimates of numbers of incidence cases and cancer deaths of 
colorectal cancer in men and women in Europe, 2000
EU, European Union; EEA, European Economic Area; APP, accession 
states; WAI, waiting list.
Source: Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: 
Cancer incidence, mortality and prevalence worldwide, Version 1.0. 
IARC CancerBases No. 5. Lyon, France: International Agency for 
Research on Cancer 2001.
Country Men Women
Cases Deaths Cases Deaths
EU Austria 2568 1407 2197 1353
Belgium 3121 1589 3073 1719
Denmark 1674 1056 1647 1067
Finland 969 491 1091 549
France 18313 8915 16 202 8221
Germany 30359 14929 30 454 17 342
Greece 1728 880 1570 839
Ireland 1049 546 807 459
Italy 17841 8739 15 474 8034
Luxembourg 122 64 129 70
The 
Netherlands
4836 2254 4463 2210
Portugal 3072 1461 2423 1211
Spain 10502 5951 8664 5001
Sweden 2731 1234 2468 1219
UK 17249 9341 15 924 9047
EU 116 134 58857 106586 58 341
EEA Iceland 54 23 43 28
Norway 1427 812 1502 841
Switzerland 1787 1042 1713 907
EEA 3268 1877 3258 1776
EU + EEA EU + EEA 119 402 60734 109844 60 117
APP Cyprus 89 44 83 43
Czech Republic 4325 2477 3130 1955
Estonia 250 147 299 185
Hungary 4235 2420 3642 2314
Latvia 371 260 498 364
Lithuania 557 404 603 404
Malta 73 46 73 40
Poland 6916 3883 6411 3994
Slovakia 1578 885 1156 726
Slovenia 539 347 490 308
Accession 
states
18933 10913 16 385 10 333
WAI Bulgaria 2116 1202 1633 996
Romania 3220 1792 2669 1614
Turkey 2472 1599 1528 984
Waiting list 7808 4593 5830 3594
Other Albania 436 238 314 169
Bosnia 
Herzegovina
756 410 609 329
Croatia 1353 831 1038 615
Macedonia 216 137 172 110
Yugoslavia 2231 1158 1850 987
Balkans 4992 2774 3983 2210
Eastern Belarus 1708 1008 1855 1080
Moldova 656 350 576 334
Russian 
Federation
25749 14162 29 587 18 012
Ukraine 9821 5392 9491 5704
Eastern 
countries
37934 20912 41 509 25 130
Table 3. Estimates of numbers of incidence cases and cancer deaths of 
lung cancer in men and women in Europe, 2000
EU, European Union; EEA, European Economic Area; APP, accession 
states; WAI, waiting list.
Source: Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: 
Cancer incidence, mortality and prevalence worldwide, Version 1.0. 
IARC CancerBases No. 5. Lyon, France: International Agency for 
Research on Cancer 2001.
Country Men Women
Cases Deaths Cases Deaths
EU Austria 2451 2487 889 866
Belgium 6256 5958 1055 968
Denmark 1999 2182 1336 1349
Finland 1443 1630 450 400
France 22910 21 652 3833 3802
Germany 33568 31 294 9403 8478
Greece 5269 4855 898 834
Ireland 941 922 538 515
Italy 29937 27 273 5689 5484
Luxembourg 191 183 47 43
The 
Netherlands
7249 7092 2207 1968
Portugal 2474 2190 512 472
Spain 16821 15 974 1552 1694
Sweden 1737 1896 1058 1176
UK 23708 24 433 13423 13231
EU 156954 150 021 42890 41280
EEA Iceland 58 54 47 45
Norway 1231 1135 649 524
Switzerland 2698 2334 745 654
EEA 3987 3523 1441 1223
EU + EEA EU + EEA 160941 153 544 44331 42503
APP Cyprus 283 257 49 44
Czech Republic 4905 4651 1181 1088
Estonia 606 560 138 126
Hungary 6526 5943 2100 1887
Latvia 880 849 161 167
Lithuania 1273 1247 213 208
Malta 117 120 17 15
Poland 17771 16 303 3948 3557
Slovakia 2100 1873 379 332
Slovenia 875 758 202 197
Accession 
states
35336 32 561 8388 7621
WAI Bulgaria 2968 2692 619 560
Romania 7352 6608 1510 1350
Turkey 10418 95 968 1152 1056
Waiting list 20738 105 268 3281 2966
Other Albania 1035 710 183 126
Bosnia 
Herzegovina
1842 1238 366 247
Croatia 2682 2283 532 430
Macedonia 563 473 111 89
Yugoslavia 5842 3495 1156 732
Balkans 11964 8199 2348 1624
Eastern Belarus 4214 3526 487 429
Moldova 1027 918 214 191
Russian 
Federation
60455 55 040 10477 9507
Ukraine 19336 17 537 3504 3162
Eastern 
countries
85032 77 021 14682 13289
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Table 4. Estimates of numbers of incidence cases and cancer deaths of 
stomach cancer in men and women in Europe, 2000
EU, European Union; EEA, European Economic Area; APP, accession 
states; WAI, waiting list.
Source: Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: 
Cancer incidence, mortality and prevalence worldwide, Version 1.0. 
IARC CancerBases No. 5. Lyon, France: International Agency for 
Research on Cancer 2001.
Country Men Women
Cases Deaths Cases Deaths
EU Austria 947 867 778 774
Belgium 982 777 664 588
Denmark 352 323 219 196
Finland 445 402 355 324
France 5109 3825 2878 2498
Germany 10 900 8805 8627 7767
Greece 1113 848 733 568
Ireland 304 242 178 146
Italy 10 206 7742 7026 5525
Luxembourg 40 32 29 26
The 
Netherlands
1498 1113 782 708
Portugal 2235 1700 1485 1150
Spain 5708 4213 3602 2869
Sweden 731 622 461 431
UK 6178 5101 3579 3199
EU 46 748 36 612 31 396 26 769
EEA Iceland 24 19 11 12
Norway 423 362 259 265
Switzerland 703 508 382 343
EEA 1150 889 652 620
EU + EEA EU + EEA 47 898 37 501 32 048 27 389
APP Cyprus 58 44 38 29
Czech Republic 1145 978 896 780
Estonia 250 211 202 158
Hungary 1794 1510 1319 1110
Latvia 394 349 335 273
Lithuania 619 540 450 346
Malta 35 35 19 15
Poland 5338 4471 2964 2491
Slovakia 642 535 397 322
Slovenia 312 277 186 196
Accession 
states
10 587 8950 6806 5720
WAI Bulgaria 1404 1180 921 777
Romania 3267 2731 1654 1396
Turkey 2785 2382 1655 1412
Waiting list 7456 6293 4230 3585
Other Albania 264 188 138 102
Bosnia 
Herzegovina
456 317 271 195
Croatia 902 718 538 431
Macedonia 370 267 192 134
Yugoslavia 1261 794 761 513
Balkans 3253 2284 1900 1375
Eastern Belarus 2913 2046 1935 1416
Moldova 546 449 328 276
Russian 
Federation
34 714 28 785 25 298 21 313
Ukraine 10 441 8657 6510 5493
Eastern 
countries
48 614 39 937 34 071 28 498
Table 5. Estimates of numbers of incidence cases and cancer deaths of 
prostate cancer in men and breast cancer in women in Europe, 2000
EU, European Union; EEA, European Economic Area; APP, accession 
states; WAI, waiting list.
Source: Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: 
Cancer incidence, mortality and prevalence worldwide, Version 1.0. 
IARC CancerBases No. 5. Lyon, France: International Agency for 
Research on Cancer 2001.
Country Prostate (men) Breast (women)
Cases Deaths Cases Deaths
EU Austria 3102 1216 4359 1754
Belgium 5128 1881 6813 2512
Denmark 1422 1069 3648 1412
Finland 2923 785 3272 834
France 28 342 10 104 37 193 11529
Germany 37 904 13 348 51 710 19 149
Greece 2273 1240 4254 1660
Ireland 1177 547 1711 666
Italy 14 197 7105 32 037 11902
Luxembourg 168 58 237 89
The 
Netherlands
6745 2486 10 880 3711
Portugal 3086 1541 4324 1596
Spain 8954 5803 14 934 6381
Sweden 6156 2508 6012 1528
UK 21 302 10 062 34 815 14 415
EU 142879 59 753 216 199 79 138
EEA Iceland 142 32 123 70
Norway 2449 1063 2334 812
Switzerland 3437 1672 4071 1682
EEA 6028 2767 6528 2564
EU + EEA EU + EEA 148907 62 520 222 727 81 702
APP Cyprus 111 60 247 93
Czech Republic 2695 1186 4598 1976
Estonia 343 138 516 228
Hungary 2925 1370 5579 2384
Latvia 316 191 839 385
Lithuania 709 363 1123 582
Malta 73 37 200 91
Poland 5920 2708 12 648 4980
Slovakia 922 465 1737 761
Slovenia 465 267 929 360
Accession 
states
14 479 6785 28 416 11840
WAI Bulgaria 1450 665 2961 1194
Romania 3076 1417 7107 2767
Turkey 1737 1050 6123 2751
Waiting list 6263 3132 16 191 6712
Other Albania 204 129 757 258
Bosnia 
Herzegovina
335 221 1373 490
Croatia 740 535 2024 825
Macedonia 160 88 500 219
Yugoslavia 958 593 3890 1399
Balkans 2397 1566 8544 3191
Eastern Belarus 1096 518 2945 1160
Moldova 273 113 1490 523
Russian 
Federation
12 869 5553 52 185 19 843
Ukraine 5159 2195 19 722 7472
Eastern 
countries
19 397 8379 76 342 28 998
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development of the disease by epidemiological studies (risk
factors). Avoiding exposure to risk determinants would result in a
reduction in cancer risk.
The evidence that cancer is preventable is compelling. Different
populations around the world experience different levels of differ-
ent forms of cancer [4], and these levels change with time in
orderly and predictable manners [5]. Groups of migrants quickly
leave behind the cancer levels of their original home and acquire
the cancer pattern of their new residence, sometimes within one
generation [6, 7]. Thus, those Japanese who left Japan for Cali-
fornia left behind the high levels of gastric cancer in their home-
land and exchanged it for the high levels of breast and colorectal
cancer present among inhabitants of their new home. Further-
more, groups whose lifestyle habits differentiate themselves from
other members of the same community frequently have different
cancer risks (c.f. Seventh Day Adventist and Mormons [8]).
For reasons such as these, it is estimated that upwards of 80%, or
even 90%, of cancers in western populations may be attributable
to environmental causes [9]; defining ‘environment’ in its broadest
sense to include a wide range of ill-defined dietary, social and cul-
tural practices. Although all of these avoidable causes have not yet
been clearly identified, it is thought that risk determinants currently
exist for about one half of cancers. Thus, primary prevention in the
context of cancer is an important area of public health.
Secondary prevention. It is very frequently the case that the prob-
ability of successful treatment of cancer is increased, sometimes
very substantially, if the cancer can be diagnosed at an early stage.
Awareness of the significance of signs and symptoms is import-
ant, but all too frequently cancers that exhibit symptoms are at
an advanced stage. ‘Screening’ is a term frequently applied to the
situation where tests are used to indicate whether an (generally
asymptomatic) individual has a high or low chance of having a
cancer. Detecting cancers at an early, asymptomatic stage could
lead to decreases in the mortality rates for certain cancers, particu-
larly for those forms of cancer in which early detection prevents
metastatic dissemination.
Tertiary prevention. An obvious way to prevent cancer death is to
cure those cancers which develop. However, there have been few
major breakthroughs in cancer treatment, in the sense of turning a
fatal tumour into a curable one. Notable successes have been in
testicular teratoma [10], Hodgkin’s disease (HD) [11], childhood
leukaemia, Wilm’s tumour and choriocarcinoma. Progress in sur-
vival from the major cancers has been very much less than hoped.
Adjuvant chemotherapy and tamoxifen have improved survival in
breast cancer [12], adjuvant chemotherapy has also contributed to
improvements in the prognosis of ovarian cancer and colorectal
cancer [13], and there has been some other progress that could be
attributed specifically to certain treatments.
General progress in medical science has led to modern anaes-
thesia making more patients candidates for surgery and surgery
safer, better control of infection and bacterial diseases, better
imaging has improved tumour localisation and staging, and better
devices are available to deliver the appropriate doses of radiation
and drugs. Thus, more patients can receive better and more appro-
priate therapy and, hence, have a better prognosis.
The quality-of-life issue has not been neglected, with breast
conservation therapy now almost supplanting traditional radical
mastectomy in the majority of women; more plastic breast recon-
struction; less amputation of limbs for bone and soft-tissue sarco-
mas; and better colostomies, being some important advances.
Against this background of cancer as an important public health
problem and one of the commonest causes of premature and
avoidable death in Europe, the European Code Against Cancer
was introduced as a series of recommendations which, if followed,
could lead in many instances to a reduction in cancer incidence
and also to reductions in cancer mortality.
The European Code Against Cancer was originally drawn-up,
and subsequently endorsed by the European Commission high-
level Committee of Cancer Experts, in 1987. In 1994, the European
Commission invited the European School of Oncology to assemble
a group of international experts to examine, and consider revision
of, the scientific aspects of the recommendations given in the
current code. This exercise took place and a new version was
adopted by the Cancer Experts Committee at its meeting in
November 1994 [1].
This publication constitutes the second revision, producing the
third version, of the European Code Against Cancer. The project
was funded by the Europe Against Cancer programme of the
European Commission. An Executive Committee was formed
to guide the project and the committee involved public health
specialists, oncologists, as well as representatives of the Cancer
Leagues and the Prevention Departments of Ministries of Health
in Europe. A Scientific Committee was established comprising
several independent experts and nominated chairmen of the sub-
committees established to review recommendations on specific
topics. More than 100 medical scientists contributed to the devel-
opment of this revision. Below the scientific rationale for each
recommended point of the European Code Against Cancer is out-
lined, as well as discussion of other factors that were considered
but not included in the code.
Many aspects of general health can be 
improved, and many cancer deaths prevented, 
if we adopt healthier lifestyles
Any recommendation made to reduce cancer occurrence should
not be one which could lead to an increased risk of other diseases.
The recommendations which comprise the revised European
Code Against Cancer should, if followed, also lead to improve-
ments in other aspects of general health (Table 6). It is also import-
ant to recognise from the outset that each individual has choices to
make about their lifestyle, some of which could lead to a reduction
in their risk of developing cancer. These choices, and the rationale
underlying their recommendation, are presented below.
1. Do not smoke; if you smoke, stop doing so. 
If you fail to stop, do not smoke in the presence 
of non-smokers.
It is estimated that between 25 and 30% of all cancer deaths in
developed countries are tobacco-related. From the results of stud-
978
ies conducted in Europe, Japan and North America, between 87
and 91% of lung cancers in men, and between 57 and 86% of lung
cancers in women, are attributable to cigarette smoking. For both
sexes combined, the proportion of cancers arising in the oeso-
phagus, larynx and oral cavity attributable to the effect of tobacco,
either acting singly or jointly with the consumption of alcohol, is
between 43 and 60%. A large proportion of cancers of the bladder
and pancreas and a small proportion of cancers of the kidney,
stomach, cervix and nose, and myeloid leukaemia are also caus-
ally related to tobacco consumption. Because of the length of the
latency period, tobacco-related cancers observed today are related
to the cigarette smoking patterns over several previous decades.
On stopping smoking, the increase in risk of cancer induced by
smoking rapidly ceases. Benefit is evident within 5 years and is
progressively more marked with the passage of time.
Smoking also causes many other diseases, most notably chronic
obstruction pulmonary disease (commonly called chronic bron-
chitis) and an increased risk of both heart disease and stroke. The
death rate of long-term cigarette smokers in middle age (35–69
years of age) is three times that of life-long non-smokers; and
approximately half of regular cigarette smokers, who started smok-
ing early in life, eventually die because of their habit. Half the
deaths take place in middle age, when the smokers lose ∼20–25
years of life expectancy compared to non-smokers; the rest occur
later in life when the loss of expectation of life is 7–8 years. There
is, however, now clear evidence that stopping smoking before
cancer or some other serious disease develops avoids most of the
later risk of death from tobacco, even if cessation of smoking
occurs in middle age (Table 7). While the rate at which young
people start to smoke will be a major determinant of ill-health and
mortality in the second half of this century, it is the extent to which
current smokers give up the habit that will determine the mortality
in the next few decades and which requires the urgent attention of
public health authorities throughout Europe.
Tobacco smoke released into the environment by smokers,
commonly referred to as environmental tobacco smoke (ETS) and
which may be said to give rise to enforced ‘passive smoking’, has
several deleterious effects on people who inhale it. It causes a
small increase in the risk of lung cancer and also some increase in
the risk of heart disease and respiratory disease, and is particularly
harmful to small children. Smoking during pregnancy increases
the risk of stillbirth, diminishes the infant’s birth weight and
impairs the child’s subsequent mental and physical development,
while smoking by either parent after the child’s birth increases
the child’s risk of respiratory tract infection, severe asthma and
sudden death.
Although the greatest hazard is caused by cigarette smoking,
cigars can cause similar hazards if their smoke is inhaled, and both
cigar and pipe smoking cause comparable hazards of cancers of
the oral cavity, pharynx, extrinsic larynx and oesophagus. There is
strong scientific evidence that smokeless tobacco, whether sucked,
chewed or inhaled, is also associated with an increased risk of
cancer.
Worldwide, it is estimated that smoking killed four million
people each year in the 1990s, and that altogether some 60 million
deaths were caused by tobacco in the second half of the twentieth
century. In most countries, the worst consequences of the ‘tobacco
epidemic’ are yet to emerge, particularly among women in
developed countries and in the populations of developing coun-
tries, as, by the time the young smokers of today reach middle or
Table 6. European Code Against Cancer (third version)
Many aspects of general health can be improved, and many 
cancer deaths prevented, if we adopt healthier lifestyles:
1. Do not smoke; if you smoke, stop doing so. If you fail to stop, do 
not smoke in the presence of non-smokers.
2. Avoid obesity.
3. Undertake some brisk, physical activity every day.
4. Increase your daily intake and variety of vegetables and fruits: eat 
at least five servings daily. Limit your intake of foods containing 
fats from animal sources.
5. If you drink alcohol, whether beer, wine or spirits, moderate your 
consumption to two drinks per day if you are a man or one drink 
per day if you are a woman.
6. Care must be taken to avoid excessive sun exposure. It is 
specifically important to protect children and adolescents. For 
individuals who have a tendency to burn in the sun active 
protective measures must be taken throughout life.
7. Apply strictly regulations aimed at preventing any exposure to 
known cancer-causing substances. Follow all health and safety 
instructions on substances which may cause cancer. Follow advice 
of National Radiation Protection Offices.
There are public health programmes that could prevent 
cancers developing or increase the probability that a cancer 
may be cured:
8. Women from 25 years of age should participate in cervical 
screening. This should be within programmes with quality control 
procedures in compliance with European Guidelines for Quality 
Assurance in Cervical Screening.
9. Women from 50 years of age should participate in breast 
screening. This should be within programmes with quality control 
procedures in compliance with European Guidelines for Quality 
Assurance in Mammography Screening.
10. Men and women from 50 years of age should participate in 
colorectal screening. This should be within programmes with 
built-in quality assurance procedures.
11. Participate in vaccination programmes against hepatitis B virus 
infection.
Table 7. Hazards for the individual cigarette user
This table has been adapted from the following source: Peto R, Lopez AD, 
Boreham J, Thun M, Heath C. Mortality from Smoking in Developed 
Countries 1950–2000. Oxford, UK: Oxford Medical Publications 1994.
Big risk, especially among those who start smoking cigarettes regularly in 
their teenage years: if they keep smoking steadily then about half will 
eventually be killed by tobacco (approximately one-quarter in old age plus 
one-quarter in middle age)
Those killed by tobacco in middle age (35–69 years) lose an average of 
20–25 years of non-smoker life expectancy
Throughout the European Union, tobacco is much the greatest single 
cause of death. In non-smokers, cancer mortality is decreasing slowly 
and total mortality is decreasing rapidly
Most of those killed by tobacco were not particularly ‘heavy’ smokers
Stopping smoking works: Even in middle age, stopping before having 
cancer or some other serious disease avoids most of the later excess risk 
from tobacco, and the benefits of stopping at earlier ages are even greater
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old age, there will be ∼10 million deaths each year from tobacco
(three million in the developed, seven million in the developing
countries). If the current prevalence of smoking persists, ∼500
million of the world’s population today can expect to be killed by
tobacco, 250 million in middle age.
The situation in Europe is particularly worrying. The European
Union is the second largest producer of cigarettes (749 billion in
1997/98) after China (1675 billion in 1998) and the major exporter
of cigarettes (400 billion). In Central and Eastern Europe, there
has been a major increase in the smoking habit. Of the six
World Health Organization (WHO) regions, Europe has the high-
est per capita consumption of manufactured cigarettes and faces
an immediate and major challenge in meeting the WHO target for
a minimum of 80% of the population to be non-smoking. In 1990–
1994, 34% of men and 24% of women in the European Union
were regular smokers. In women, the rates were reduced by the
low rates in southern Europe, but the rates there are rising and
seem set to continue to rise over the next decade. In the age range
25–39 years, the rates are higher (55% in men and 40% in women)
and this can be expected to have a profound influence on the future
incidence of disease. It is particularly disturbing that in many parts
of Europe, the prevalence of smoking remains high among general
practitioners, who should set an exemplary lifestyle in terms of
health. This should be a target for immediate action.
It has been shown that changes in cigarette consumption are
affected mainly at a sociological level rather than by actions
targeted at individuals (for example, individual smoking cessation
programmes). Actions such as advertising bans and increases in
the price of cigarettes influence cigarette sales particularly among
the young. A ‘tobacco policy’ is consequently essential to reduce
the adverse health effects of tobacco, and experience shows that
this should be aimed at both stopping young people from starting
to smoke and helping smokers to stop. To be efficient and success-
ful, a tobacco policy has to be comprehensive and maintained over
a long time period. Increased taxes on tobacco, total bans on direct
and indirect advertising, smoke-free enclosed public areas, prom-
inent health warning labels on tobacco products, a policy of low
maximum tar levels in cigarettes, education about the effects of
smoking, encouragement of smoking cessation, and health inter-
ventions at the individual level, all need to be implemented. It
must be recognised that nicotine is an addictive drug and that
some smokers who are heavily addicted need medical help to
overcome the addiction.
The importance of adequate intervention is shown by the low
lung cancer rates in those Nordic countries which, since the early
1970s, have adopted integrated central and local policies and pro-
grammes against smoking. In the UK, tobacco consumption has
declined by 46% since 1970 and lung cancer mortality among men
has been decreasing since 1980, although the rate still remains
high. In France, between 1993 and 1998, there has been a 11%
reduction in tobacco consumption due to the implementation of
antitobacco measures introduced by the Loi Evin.
The first point of the European Code Against Cancer is conse-
quently:
Do not smoke. Smoking is the largest single cause of premature
death.
If you smoke, stop doing so. In terms of health improvement, stop-
ping smoking before having cancer or some other serious disease
avoids most of the later excess risk of death from tobacco even if
smoking is stopped in middle age.
If you fail to stop, do not smoke in the presence of non-smokers.
The health consequences of your smoking may affect the health of
those around you.
2. Avoid obesity.
3. Undertake some brisk, physical activity 
every day.
In this section, the adverse effect of obesity (or being overweight)
and the protective effect of physical activity on cancer risk are
summarised. It is based on the evidence from a comprehensive
review on weight control and physical activity published by the
International Agency for Research on Cancer (IARC). Because of
the relationship between obesity and physical activity it is import-
ant to separate the effects of the two.
Obesity
Obesity is an established major cause of morbidity and mortality.
It is the largest risk factor for chronic disease in western countries
after smoking, particularly increasing the risk of diabetes, cardio-
vascular disease and cancer. Most countries in Europe have seen
the prevalence of obesity [defined as a body mass index (BMI) of
≥30 kg/m2; Figure 1] rapidly increase over the years. The preva-
lence ranges from <10% in France to ∼20% in the UK and Ger-
many and higher in some central European countries (>30%). It is
associated with an increased risk of cancer at several sites and the
evidence is clear for cancer of the colon, breast (postmenopausal),
endometrium, kidney and oesophagus (adenocarcinoma). There is
still an excess risk after allowing for several factors, such as phy-
sical activity. Overweight (BMI of 25–29 kg/m2) is similarly
associated with these cancers though the effect on risk is less.
The risk of colon cancer increases approximately linearly with
increasing BMI between 23 and 30 kg/m2. Compared with having
a BMI <23 kg/m2 the risk increases ∼50–100% in people with a
BMI ≥30 kg/m2. The association appears to be greater in men than
in women. For example, in the American Cancer Society cohort
study of ∼1.2 million people, the increase in risk of colon cancer in
those with a BMI ≥30 kg/m2 was 75% in men and 25% in women
compared to those with a BMI <25 kg/m2. The evidence also
suggests that the risk does not depend on whether the person had
been overweight in early adulthood or later in life.
Over 100 studies have consistently shown a modest increased
risk of breast cancer in postmenopausal women with a high body
weight. On average, epidemiological studies have shown an increase
in breast cancer risk above a BMI of 24 kg/m2. A pooled analysis
of eight cohort studies of ∼340000 women showed an increase in
risk of 30% in women with a BMI ≥28 kg/m2 compared to those
with a BMI of <21 kg/m2. Factors that have been shown to atten-
uate the association between obesity and breast cancer include
family history (heavier women with a family history of breast
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cancer have a higher risk than similar women without a family his-
tory) and the use of hormone replacement therapy (HRT) (the risk
of breast cancer associated with obesity is greater in women who
had never used HRT). In contrast, among premenopausal women
obesity is not associated with an increase in risk of breast cancer.
There is consistent evidence that being overweight is associated
with an increased risk of endometrial cancer. Women with a BMI
of >25 kg/m2 have a two- to three-fold increase in risk. Although
limited, the evidence suggests that the risk is similar in pre- and
postmenopausal women. There is evidence that the risk is greater
for upper-body obesity.
The association between kidney (renal cell) cancer and BMI is
also well established and is independent of blood pressure. Indi-
viduals with a BMI of ≥30 kg/m2 have a two- to three-fold
increase in risk compared with those below 25 kg/m2. The effect is
similar in men and women. There is a similarly strong association
between being overweight and adenocarcinoma of the lower
oesophagus and the gastric cardia; about two-fold increase in
risk in individuals with a BMI of >25 kg/m2. A modest association
has been reported in a pooled analysis of BMI and thyroid cancer
(the increase in risk in those in the highest third of BMI was
20% in women and 50% in men). The evidence on obesity and
gallbladder cancer is limited but there is a suggestion of almost a
two-fold increase in risk, especially in women.
In Western Europe, it has been estimated that being overweight
or obese accounts for ∼11% of all colon cancers, 9% of breast
cancers, 39% of endometrial cancers, 37% of oesophageal adeno-
carcinomas, 25% of renal cell cancer and 24% of gallbladder
cancer.
Physical activity
Many studies have examined the relationship between physical
activity and the risk of developing cancer. There is consistent
evidence that some form of regular physical activity is associated
with a reduction in the risk of colon cancer. There is also a sugges-
tion of a risk reduction in relation to cancer of the breast,
endometrium and prostate. The protective effect of physical activ-
ity on cancer risk improves with increasing levels of activity (the
more the better) though such a recommendation should be moder-
ated in individuals with cardiovascular disease. Regular physical
activity that involves some exertion may be needed to maintain
a healthy body weight, particularly for people with sedentary life-
styles. This could involve half an hour per day three times per
week. More vigorous activity several times per week may give
some additional benefits regarding cancer prevention.
For some cancers, the preventive effect of regular physical
activity seems to act independently of weight control. The preven-
tion of weight gain and obesity and the promotion of exercise
should ideally begin early in life. However, the benefits can also
be gained later in life if a healthy lifestyle is adopted. It is desirable
to maintain a BMI in the range of 18.5–25 kg/m2, and people who
are already overweight or obese should aim to reduce their BMI to
<25 kg/m2. A lifestyle that incorporates a healthy diet, exercise
and weight control is beneficial to the individual not only with
regards to cancer but also other diseases.
4. Increase your daily intake and variety of 
vegetables and fruits: eat at least five servings 
daily. Limit your intake of foods containing 
fats from animal sources.
Diet and nutritional factors started to be the focus of serious atten-
tion in the aetiology of cancer from the 1940s onwards. Originally
dealing with the effect of feeding specific diets to animals receiv-
ing chemical carcinogens, research turned to the potential of
associations with human cancer risk. Initially, this was conducted
through international comparisons of estimated national per capita
food intake data with cancer mortality rates. It was consistently
found that there were very strong correlations in these data, par-
ticularly with dietary fat intake and breast cancer. As dietary
assessment methods became better, and certain methodological
difficulties were identified and overcome, the science of Nutri-
tional Epidemiology emerged.
Doll and Peto estimated that somewhere between 10 and 70%
of all cancer deaths were associated with dietary and nutritional
practices, with the best estimate ∼30%. In 1983, the United States
Academy of Science concluded that, after tobacco smoking, diet
and nutrition was the single most important cause of cancer. Since
then, the epidemiological search has been to improve knowledge of
the exact relationships between food and nutrition and cancer risk
and to identify associations with particular components of diet and
determine the best intervention strategy.
Figure 1. Calculation of body mass index from height and weight.
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Initially, much attention focused on intake of fat in the diet,
particularly from animal sources. Although the results from
ecological studies and data from animal experiments were very
strong regarding this association, findings from retrospective and
prospective epidemiological studies have been inconsistent, par-
ticularly regarding the association with breast cancer and colorectal
cancers.
A number of epidemiological studies indicate a protective
effect of higher intakes of vegetables and fruit on the risk of a
wide variety of cancers, in particular oesophagus, stomach, colon,
rectum and pancreas. A higher consumption of vegetables and
fruits has been associated with a reduced risk of cancer at various
sites in several studies from Europe, mostly using a case–control
design. The relation is however less consistent in data from several
cohort studies from North America. If any, the association was
apparently most marked for epithelial cancers, in particular those
of the alimentary and respiratory tract, although such an asso-
ciation is weak to non-existent for hormone-related cancers.
Cereals with high fibre content and whole-grain cereals have
been associated with lower risk of colorectal cancer and other
digestive tract tumours in a few European studies. However,
several large cohort and randomised intervention studies have not
supported this association. The EPIC (European Prospective
Investigation into Cancer and Nutrition) study, examined this
association in 519978 individuals aged 25–70 years, recruited
from 10 European countries. Follow-up consisted of 1939011
person-years, and data for 1065 reported cases of colorectal
cancer were included in the analysis. Dietary fibre in foods was
inversely related to incidence of large bowel cancer {adjusted
relative risk 0.75 [95% confidence interval (CI) 0.59–0.95] for
the highest versus lowest quintile of intake}, the protective effect
being greatest for the left side of the colon, and least for the
rectum. After calibration with more detailed dietary data, the
adjusted relative risk for the highest versus lowest quintile of fibre
from food intake was 0.58 (95% CI 0.41–0.85). No food source of
fibre was significantly more protective than others, and non-food
supplement sources of fibre were not investigated. The authors
concluded that in populations with low average intake of dietary
fibre, an approximate doubling of total fibre intake from foods
could reduce the risk of colorectal cancer by 40%.
The confusing nature of this association between fibre intake
and colorectal cancer risk is highlighted by the simultaneous
publication of two studies, one of which confirmed this finding
and another which reported no association.
Lower rates of many forms of cancer reported in southern Euro-
pean regions, like in Southern Europe, have been attributed to a
diet lower in meats and fats from animal sources, and higher in
fish, olive oil, vegetables and fruits, grains and moderate alcohol
consumption. While a link has been suggested, this has not yet
been proved convincingly.
The association with reduced risk of cancer exists for a wide
variety of vegetables and fruits. There also exists increasing
evidence that consumption of higher levels is also beneficial for
other chronic diseases. Vegetables and fruits contain a large
number of potentially anticarcinogenic agents, with complement-
ary and overlapping mechanisms of action. However, the exact
molecule(s) in vegetables and fruits that confers this protection is
unknown. Insight into the mechanisms of action is only incom-
plete, but this is not required for public health recommendations.
It is, in any case, not possible to recommend dietary supplementa-
tion with vitamins and minerals to reduce cancer risk based on the
evidence currently available.
Nonetheless, it is difficult to be precise about the advisable
quantity of fruits and vegetables and it is difficult to imagine the
successful implementation of a randomised trial of increased
consumption of fruits and vegetables. The best available evidence
comes from observational studies and the search continues for the
molecule(s) in fruits and vegetables responsible for the apparent
protection.
Fruits and vegetables should be taken with each meal whenever
possible, and systematically replace snacks between meals. In line
with WHO and USA recommendations, ‘five-a-day’ (minimum
400 g/day, i.e. two pieces of fruit and 200 g of vegetables) is advo-
cated, which could lead to a reduction in cancer risk. Particular
attention regarding changing nutritional practices needs to be paid
to the countries of central and Eastern Europe, where rapid changes
in dietary patterns have been shown to have had a rapid positive
influence on death rates from chronic disease.
5. If you drink alcohol, whether beer, wine or 
spirits, moderate your consumption to two 
drinks per day if you are a man or one drink 
per day if you are a woman.
There is wide variability among European Union countries in
terms of per capita average alcohol consumption and preferred
type of alcoholic beverage (Figure 2). Although three groups of
countries are traditionally identified according to the prevalent
drinking culture (wine drinking in the South, beer drinking in the
Central Europe and spirit drinking in the North), there is consider-
able variability within such groups and within countries, and new
patterns are evolving rapidly (e.g. increasing consumption of wine
in northern countries; increasing prevalence of binge drinking, in
particular among women).
There is convincing epidemiological evidence that the con-
sumption of alcoholic beverages increases the risk of cancers of
the oral cavity, pharynx and larynx and of squamous cell carcin-
oma of the oesophagus. The risks tend to increase with the amount
of ethanol drunk, in the absence of any clearly defined threshold
below which no effect is evident.
Although alcohol drinking increases the risk of upper digestive
and respiratory tract neoplasms, even in the absence of smoking,
alcohol drinking and tobacco smoking together greatly increase
the risk of these cancers, each factor approximately multiplying
the effect of the other. Compared to never-smokers and non-
alcohol drinkers, the relative risk of these neoplasms is increased
between 10- and 100-fold in people who drink and smoke heavily
(Figure 3). Indeed, in the case of total abstinence from drinking
and smoking, the risk of oral, pharyngeal, laryngeal and squamous
cell oesophageal cancers in European countries would have been
extremely low.
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A likely carcinogenic mechanism of alcohol is by facilitating
the carcinogenic effect of tobacco and possibly of other carcino-
gens to which the upper digestive and respiratory tract are exposed,
particularly those of dietary origin. However, a direct carcino-
genic effect of acetaldehyde, the main metabolite of ethanol, and
of other agents present in alcoholic beverages cannot be excluded.
A diet poor in fruits and vegetables, typical of heavy drinkers, is
also likely to play an important role. There does not seem to be a
different effect of beer, wine or spirits on cancer risk at these sites;
rather the total amount of ethanol ingested appears to be the key
factor in determining the increase in risk. Only a few studies have
analysed the relationship between stopping alcohol drinking and
the risk of cancers of the upper respiratory and digestive tract.
There is clear evidence that the risk of oesophageal cancer is
reduced by 60% 10 years or more after drinking cessation. The
pattern of risk is less clear for oral and laryngeal cancers. Stopping
(or reducing) alcohol drinking, particularly in association with
smoking cessation, represents a priority for preventing oeso-
phageal cancer.
Alcohol drinking is also strongly associated with the risk of
primary liver cancer; the mechanism however might be mainly
or solely via the development of liver cirrhosis, implying that light
or moderate drinking may have limited influence on liver cancer
risk. Moreover, there is some evidence suggesting that heavy
alcohol consumption is particularly strongly associated with liver
cancer among smokers and among people chronically infected
with hepatitis C virus (HCV).
An increased risk of colorectal cancer has been observed in
many cohort and case–control studies, which seems to be linearly
correlated with the amount of alcohol consumed and independent
from the type of beverage.
An increased risk of breast cancer has been consistently
reported in epidemiological studies conducted in different popu-
lations. Although not strong (increased risk in the order of 10%
for each 10 g/day increase in alcohol intake, possibly reaching a
plateau at the highest levels of intake), the association is of great
importance because of the apparent lack of a threshold, the large
number of women drinking a small amount of alcohol and the high
incidence of the disease. Indeed, more cases of breast cancer than
of any other cancer are attributable to alcohol drinking among
European women (Table 8). It has been suggested that alcohol acts
on hormonal factors involved in breast carcinogenesis, but the
evidence is currently inadequate to identify a specific mechanism.
Besides increasing cancer risk, alcohol drinking entails complex
health consequences, making it difficult to formulate universal
public health guidelines. There is strong evidence for a J-shaped
pattern of risk of total mortality and cardiovascular disease
according to increasing alcohol consumption (Figure 4). This
classic pattern is one of decreased risk in light drinkers compared
with non-drinkers and then an increasing risk as alcohol consump-
tion increases. In addition, alcohol drinking increases the risk of
injuries in many types of motor vehicle, leisure and occupational
injuries (e.g. driving, swimming, manual working) and accident
mortality rates are influenced by per capita alcohol consumption
across Europe. Moreover, drinking alcohol during pregnancy has
a detrimental effect on the development of the foetus and its
Figure 2. Recorded per capita alcohol consumption among adults in selected European Union and accession countries, by type of beverage (1996).
Figure 3. Relative risk of laryngeal cancer for tobacco smoking and alcohol 
drinking in a study from Southern Europe. Ref, reference category (risk = 1).
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central nervous sytem, often resulting in malformations, behavioural
disorders and cognitive deficits in the postnatal period.
For these reasons, the task of fixing a threshold on daily alcohol
intake below which the increased risk of cancer and other diseases
is offset by a reduced risk of cardiovascular diseases is not simple.
Factors such as age, physiological condition and dietary intake
certainly modify any such threshold: in particular, the beneficial
effects on cardiovascular diseases appear only at middle age.
In conclusion, there is evidence showing that a daily alcohol
intake as low as 10 g/day (that is, approximately, one can of beer,
one glass of wine or one shot of spirit) (Figure 5) is associated with
some increase in breast cancer risk relative to non-drinkers, while
the intake associated with a significant risk of cancer at other sites
(such as cancers of the upper digestive and respiratory tracts, liver
or colorectum) is probably somewhat higher (∼20–30 g/day).
All the above points should be considered to give sensible
advice regarding individual recommended limits of alcohol con-
sumption. The limit should not exceed between 20 g of ethanol per
day (i.e. approximately two drinks of either beer, wine or spirit
each day) and it should be as low as 10 g per day for women.
6. Care must be taken to avoid excessive sun 
exposure. It is specifically important to protect 
children and adolescents. For individuals who 
have a tendency to burn in the sun active 
protective measures must be taken throughout 
life.
Skin cancer is predominantly, but not exclusively, a disease of
white skinned people. Its incidence, furthermore, is greatest where
fair skinned peoples live at increased exposure to ultraviolet (UV)
light, such as in Australia. Figure 6 shows the marked latitudinal
gradient in age-related incidence of melanoma, the form of skin
cancer most likely to metastasise and cause death. The main
environmental cause of skin cancers is sun exposure, and UV light
is deemed to represent the component of the solar spectrum
involved in skin cancer occurrence.
The type of sun exposure which causes skin cancer however
appears to differ in the three main types. Squamous cell carcinoma
shows the clearest relationship with cumulative sun exposure.
This form of skin cancer is therefore most common in outdoor
workers. The recipients of transplanted organs are particularly at
risk of these tumours as a result of the combined effects of the
unchecked growth of human papilloma virus (HPV) in their skin
due to immunosuppression, and exposure to the sun. Basal cell
carcinoma is the commonest type of skin cancer but it is the least
serious as it is a local disease only. This form of skin cancer
appears to share an aetiological relationship to sun exposure with
melanoma.
The risk of cutaneous melanoma appears to be related to inter-
mittent sun exposure. Examples of intermittent sun exposure are
sunbathing activities and outdoor sport activities. Also, a history
of sunburn has repeatedly been described as a risk factor for
melanoma, which again is associated with intermittent sun
exposure.
The incidence of melanoma has doubled in Europe between the
1960s and the 1990s and this is attributed to increased intense sun
Table 8. Estimated number and proportion of cancer cases 
attributable to alcohol consumption in European Union (1995)
Sources: All information taken from Pisani P. Avoidable Cancer in 
Europe: Estimating Etiologic Fractions. Final Report to the 
European Commission, Contract No. 96-200504. Lyon, France: 
International Agency for Research on Cancer 2000. The exception 
is breast cancer, which was calculated based on a relative risk of 1.1 
and prevalence of exposure of 30%.
Cancer Men Women
n % n %
Oral Cavity and Pharynx 13 900 36 2700 29
Oesophagus 7400 41 2100 34
Liver 3300 17 500 25
Larynx 6600 30 1200 13
Breast 6000 3
Figure 4. Annual mortality by alcohol consumption for all causes of death 
in men. One unit of alcohol (a glass of beer, wine or spirits) corresponds to 
8–10 g of ethanol. Source: Doll R, Peto R, Hall E et al. Mortality in relation 
to consumption of alcohol: 13 years’ observations on male British doctors. 
BMJ 1994; 309: 911–918.
Figure 5. One unit of alcohol. From left to right: a glass of wine, a glass of 
beer, and a shot of whisky.
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exposure, which has taken place this century. The incidence of
squamous cell and of basal cell cancers has also increased in all
European countries. Although much less life threatening than
melanoma, these tumours represent 95% of all skin cancers, and
their treatment amount to considerable costs for individuals and
social security systems.
The advice to the European population must therefore be to
moderate sun exposure: to reduce their total life-time exposure,
and in particular to avoid extremes of sun exposure and sunburn.
All Europeans however are not equally susceptible to skin cancer.
The fairest are more susceptible, particularly those with red hair
(but not exclusively), freckles and a tendency to burn in the sun.
The strongest phenotypic risk factor for melanoma however is
the presence of large numbers of moles or melanocytic naevi, and
twin study evidence is strong that the major determinant of naevus
number is genetic with an added contribution from sun exposure.
These naevi may be normal in appearance but are also usually
accompanied by so-called atypical moles: moles which are larger
than 5 mm in diameter with variable colour within and an irregular
shape. The phenotype is described as atypical mole syndrome
(AMS). The AMS is present in something like 2% of the north
European population and is associated with an approximately ten
times increased risk of melanoma. Advice about sun protection
is therefore particularly of importance to this sector of the popu-
lation. Some patients with the AMS report a family history, and
overall a strong (three or more cases) family history is the greatest
predictor of risk. These families should avoid the sun and should
be referred to dermatologists for counselling.
The best protection from the summer sun is to stay out of it, but
the following advice is given in order to allow safer enjoyment
of the outdoors. Keeping out of the sun between 11 am and 3 pm
is effective as UV exposure is greatest at this time. Therefore,
scheduling outdoor activities for other times is important, par-
ticularly for children. Using shade is allied to this and clothing
remains the second most important measure. Close weave heavy
cotton affords good protection although the clothing industry is
increasingly developing UV protective clothes with high sun
protection properties, which are very valuable particularly where
it is difficult to keep out of the sun.
Sunscreens are useful for protection against sunburns of skin
sites such as the face and the ears. Sunscreen may protect against
squamous cell carcinoma but there is currently inadequate evi-
dence for their preventive effect against basal cell carcinoma
and melanoma. However it is extremely important when using
sunscreen to avoid prolongation of the duration of sun exposure
that may be responsible for an increased risk of melanoma. Addi-
tionally, there is evidence that using higher SPF sunscreen pro-
longs further time spent in the sun. Great care should be taken
when choosing to use sunscreen and also in the choice of SPF. In
addition, sunbed use is also discouraged, as exposure to these
devices resembles the type of sun exposure mostly associated with
melanoma occurrence.
7. Apply strictly regulations aimed at 
preventing any exposure to known cancer-
causing substances. Follow all health and safety 
instructions on substances which may cause 
cancer. Follow advice of national radiation 
protection offices.
The prevention of exposure to occupational and environmental
carcinogens has followed the identification of a substantial number
of natural and man-made carcinogens, and has led to significant
reductions in cancer occurrence. The message in this item of
the code solicits responsible behaviour for individuals in three
respects: (i) from those who have to provide timely and clear
instructions, primarily legislators and regulators who should adapt
Figure 6. Age-specific incidence of melanoma in various countries.
985
scientific consensus evaluations into European Union law, and
control compliance with these regulations; (ii) from those who
should follow these instructions and comply with the laws to pro-
tect the health of others, for instance, managers, hygienists and
doctors in industry; and (iii) from every citizen who in order to
protect their own health and the health of others, ought to pay heed
to the presence of carcinogenic pollutants and follow instructions
and regulations aimed at mitigating or preventing exposure to
carcinogens. The latter applies to a wide variety of circumstances
such as traffic restrictions within cities, restrictions on smoking,
use of personal safety devices and respecting validated procedures
in the workplace. Application of regulations is particularly import-
ant in the working environment where carcinogens may be found
in higher concentrations than in the general environment. The
control of the prevalence and level of exposure to occupational
and environmental carcinogens through general preventive meas-
ures has historically played a more important role in preventing
cancers than individual measures of protection.
The cancers that have most frequently been associated with
occupational exposures are those of the lung, urinary bladder,
mesothelioma, larynx, leukaemia, angiosarcoma of the liver, nose
and nasal cavity and skin (non-melanoma). Several other neo-
plasms have also been associated with occupational exposures but
the evidence is less strong. They include cancers of the oral cavity,
nasopharynx, oesophagus, stomach, colon and rectum, pancreas,
breast, testis, kidney, prostate, brain, bones, soft-tissue sarcoma,
lymphomas and multiple myeloma. Most known or suspected
occupational carcinogens have been evaluated by the IARC
(Lyon, France). Actually, 29 chemical or physical agents, groups
of agents or mixtures that occur predominantly in the workplace,
have been classified as human carcinogens (Group 1 of the IARC
classification). In the same Group 1, IARC has classified 13
industrial processes or occupations, such as the rubber industry,
painters, etc. In European Union countries, production or use of
some of these chemicals has been banned and are only of his-
torical interest (e.g. mustard gas, 2-naphthylamine), while some
high-risk industries have stopped functioning (e.g. ‘Wismut’
uranium ore mining associated with exposure to ionising radia-
tion). Exposure to other carcinogens such as metals and dioxins is
still widespread.
Thirty-five agents or industrial processes are classified as prob-
ably carcinogenic to humans (Group 2A of the IARC). Many
of the agents in this group are still widely used, for example 1,3-
butadiene and formaldehyde. More than 200 agents, groups of
agents or exposure circumstances are classified as possibly
carcinogenic to humans (Group 2B) largely on the basis of
carcinogenicity data from animal experiments. It has been esti-
mated that in the early 1990s about 32 million workers (23% of
those employed) in the European Union were exposed to carcino-
genic agents at levels above background. Exposure to these agents
is still widespread but occurs mostly at low levels. The more
common occupational exposures are solar radiation, passive
smoking, crystalline silica, diesel exhaust, radon, wood dust, ben-
zene, asbestos, formaldehyde, polycyclic aromatic hydrocarbons,
chromium VI, cadmium and nickel compounds.
Extensive preventive measures in the workplace in recent
decades have resulted in the prevention of many cancers related
to workplace exposures. This has been well documented, for
example for occupational bladder cancer after the ban on the use
of β-naphthylamine in the rubber and chemical industries. The
delays in taking protective measures, however, and the long
latency for many neoplasms will result, in certain instances, in a
continuous increase in the number of occupational cancers during
the coming years. An increasing number of mesothelioma cases
due to past occupational exposure to asbestos is expected in many
European Union countries for another 10–20 years, even though
asbestos has been banned in some European Union countries since
the early 1990s. The proportion of all cancers that can be causally
attributed to carcinogens in the occupational environment and are
therefore wholly or partially avoidable through exposure control,
remains difficult to quantify reliably. An estimated 5% of cancers
is attributable to the occupational environment. This proportion
depends on the variable prevalence of the exposures by geograph-
ical areas, gender, socioeconomic status and periods of time, as
well as on the concurrent prevalence of other dominant cancer
causing factors, particularly tobacco smoking. Furthermore, the
effect of specific occupational carcinogens, such as aromatic
amines or polycyclic aromatic hydrocarbons, is also mediated by
genetic factors, such as genetic polymorphisms of the NAT2 or
GSTM1 genes. The distribution of these polymorphisms within
the populations of the European Union is fairly uniform and
genetic factors probably do not determine differences in the pro-
portion of occupational cancers between populations in European
Union countries.
Environmental exposures usually refer to exposures of the
general population that cannot be directly controlled by the indi-
vidual. They include air-pollution, drinking water contaminants,
passive smoking, radon in buildings, exposure to solar radiation,
food contaminants such as pesticide residues, dioxins or environ-
mental estrogens, chemicals from industrial emissions, and oth-
ers. Exposure may be widespread, as is the case for air pollution,
or could be restricted, as would be the case of populations living in
the vicinity of a contaminating industry. These exposures have
been associated with a variety of neoplasms, including cancers of
the lung, urinary bladder, leukaemia and skin. The impact of several
environmental carcinogenic exposures, such as arsenic in drinking
water, has not been quantified, though exposure to arsenic is likely
to affect only limited population groups. Air pollutants, such as
fine particles, have been associated in several studies with a small
increased risk of lung cancer even at current low-level urban
exposure levels. The evidence on other exposures that are wide-
spread, such as disinfection by-products in drinking water, is still
inconclusive. Agents in the general environment to which a large
number of subjects are exposed for long periods, such as passive
smoking or air-pollution, although increasing only modestly the
relative risk for certain cancers may be at the origin of several
thousand cases per year in the European Union.
It is essential that for any agent liable to present a risk, the
nature, degree and duration of such risk must be determined in
order to define what measures need to be taken to prevent or
reduce the exposure. Among these measures, suitable operating
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procedures and methods are of utmost importance. Instructions to
be followed may take the form of quantitative control limits of
exposure, derived empirically or through formal procedures, which
still leaves much to be desired. The specification of a quantitative
control limit of exposure in the general and occupational environ-
ment combines two elements: the quantitative estimate of the
risk associated with a given level of exposure and the level of
risk regarded as socially ‘acceptable’, with consideration of the
technical feasibility, and human and economic costs of various
degrees of control.
Ionising and non-ionising radiation
Ionising radiation at high doses causes cancer in humans: only a
few cancer types have never been related to ionising radiation.
This has been known for decades, and excellent summaries of
the scientific literature are available. The IARC recently classified
X-rays, γ-rays and neutrons as carcinogenic to humans (Group 1).
This is irrespective of the different patterns of energy release and
penetrating power of the different types of ionising radiation.
Energy at high levels may lead to cellular and DNA damage
followed by cell killing, whereas at lower doses it may lead to
mutations increasing the risk of cancer. The International Com-
mission on Radiological Protection (ICRP) issues recommenda-
tions for radiological protection based on the existing scientific
literature.
High-dose ionising radiation is used in medicine to treat cancer.
These types of exposures are at present outside the scope of the
European Code Against Cancer. However, much of our evidence
on the effects of ionising radiation on humans is derived from such
uses, and from the atomic bomb survivors at Hiroshima and
Nagasaki. The main source of radiation to the human population
comes from the natural background, both terrestrial and cosmic
(Table 9), whilst the man-made sources, such as atmospheric
nuclear testing, nuclear accidents (e.g. Chernobyl) and nuclear
power production, which cause the most public concern, cause
only very little exposure (Table 9).
The United Nations Scientific Committee on the Effects of
Atomic Radiation (UNSCEAR) estimates the population risk of
dying from cancer after an acute dose of 1000 mSv is about 9% for
men and 13% for women. The estimates could be reduced by 50%
for chronic exposures. The worldwide average annual effective
dose is 2.4 mSv. The lifetime exposure of the population to all
sources of ionising radiation was estimated by the National Radio-
logical Protection Board to account for 1% of all fatal cancers in the
UK (http://www.nrpb.org/radiation_topics/risks/cancer_risk.htm,
22 November 2002). Only 1% of this risk is ascribed to the small
doses from man-made radiation.
For the purpose of the European Code Against Cancer, this
review concentrates on the possible effects of the natural back-
ground radiation, terrestrial (in the form of radon gas) and cosmic
radiation, as it is possible to control exposure to both. Further-
more, we assess the cancer risk related to the Chernobyl accident
and that among nuclear workers and people living near nuclear
installations. Diagnostic radiation is of concern for the population
groups undergoing examinations, be it screening of healthy indi-
viduals with mammography or computed tomography (CT) scans
for lung cancer or when there is a suspicion of thyroid disease.
Screening with low-dose CT for lung cancer is reported to give an
effective dose of between 0.2 and 1 mSv. Using the risk factor of
5% per 1 Sv (ICRP 60), this would imply one to five radiation
induced fatal cancers per 100 000 examinations. Mammography
screening for breast cancer typically gives an absorbed average
glandular dose of 3 mGy. It has been estimated in Sweden that
among women aged 50–69 years, with a reduction in breast cancer
mortality due to a mammographic screening programme of 25%,
that 560 deaths from breast cancer would be avoided. It is esti-
mated that the effect of the radiation would be to induce between 1
and 5 fatal breast cancers per 100000 examinations. Although the
collective dose from diagnostics to the population is small relative
to natural radiation, benefit analyses should be performed to avoid
unnecessary exposure.
Non-ionising radiation from sources such as power lines, elec-
trical equipment, mobile phones and solar radiation raise public
concern as to a possible carcinogenic effect. The ICNIRP (Inter-
national Commission on Non-ionising Radiation Protection) issues
guidelines for limiting exposure, and the German Stralenschutz-
kommission and the UK NRPB recently published reviews
assessing the health risks. The evidence on power lines and mobile
phones are dealt with in this section, whereas solar radiation is
dealt with separately.
Radon and cancer. Radon-222 is a naturally occurring chemically
inert gas, which arises from the decay chain of uranium in the
earth’s crust. Inhalation of air containing radon and its products
results in the exposure of cells in the bronchial epithelium and
elsewhere to ionising radiation, chiefly from α-particles. Surveys
have indicated that radon accounts for an average annual effective
dose of 1.15 mSv worldwide, almost half the total annual effective
dose from all natural sources of radiation. There is very wide
variation in levels of radon exposure and a number of populations
are exposed to levels that are more than a factor of ten higher than
the overall average. The majority of exposure to radon occurs
indoors, especially in homes, where the principal source is usually
the subsoil, although under some circumstances appreciable
exposure may occur from building materials or from radon dis-
solved in water.
Table 9. Sources of ionising radiation to man
aAverage radiation doses for 2000 from natural and man-made sources of 
radiation.
Source: UNSCEAR, 49th session, Vienna, 2–11 May 2000, 
www.unscear.org/press_releases.htm (23 March 2003, date last accessed).
Source Worldwide average annual effective 
dosea, millisievert (mSv)
Natural background 2.4
Diagnostic medical examinations 0.3
Atmospheric nuclear testing 0.005
Chernobyl accident 0.002
Nuclear power production 0.001
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There is conclusive evidence from studies of underground
miners occupationally exposed to high concentrations of radon in
air that radon is a cause of lung cancer. Extrapolation from the
miners’ studies to the likely effects of environmental exposure to
radon suggests that radon should be the second most important
cause of lung cancer in the general population after cigarette
smoking, and that the majority of radon-induced lung cancers are
in those who smoke cigarettes or who have smoked them in the
past. Direct studies of the risk of lung cancer from residential
radon exposure are consistent with these conclusions. The studies
of underground miners and also some direct studies suggest that
high concentrations of radon in air do not cause a material risk of
death from cancers other than lung cancer.
When a new house or other building is being constructed, it
is usually possible, for a minimal cost, to ensure that the radon
concentration inside the building will be very low. For existing
buildings it is also usually possible at some cost to reduce the
radon concentrations. In terms of risk reduction, such measures
will have their biggest effect on smoking inhabitants.
Cosmic radiation and cancer. Recently, several epidemiological
studies have been carried out to investigate cancer mortality and
cancer incidence among airline crew. Many exposure studies have
been conducted to estimate and to measure the dose of cosmic
radiation at flight altitudes of jet aircraft. The latter studies con-
clude that a typical annual radiation dose is between 3 and 6 mSv
for a commercial pilot. Values up to 9 mSv have been estimated
for a pilot flying some 600 h/year on polar flights at 10 km and
above. Detailed assessment of individual flight history has showed
that for all pilots the lifetime cumulative exposure was below
100 mSv. Results of the mortality studies and incidence studies
are as yet inconclusive, although for most cohorts the total cancer
(mortality and incidence) was not raised compared with the gen-
eral population. For specific cancer sites, increased and decreased
standardised mortality or incidence ratios were observed without
a clear pattern. Leukaemia risk is not increased, with the exception
of a study of Danish pilots, based on only 14 cases. A more con-
sistent finding is an increased risk of breast cancer, which is also
a cancer associated with radiation. The role of risk factors other
than radiation, such as late first childbirth and low parity, may not
always have been fully taken into account when evaluating these
findings. Another consistent finding is an increase in skin cancer
and melanoma. Whether this is related to leisure activities, occu-
pational factors or a combination of both needs further investiga-
tion.
The overwhelming evidence does not point to a significant
adverse health effect in terms of cancer, and the present regulation
of aircrew as radiation workers sufficiently controls the occu-
pational exposure. Very few passengers will ever accumulate
radiation doses from cosmic radiation in the same magnitude as
the staff and hence no particular precautions need to be taken.
Radioiodine and thyroid cancer. Ionising radiation is the only
definitely established cause of thyroid cancer in humans, although
only a small proportion of thyroid cancers can be accounted for
by radiation. The thyroid gland is highly susceptible to ionising
radiation presumably because of its superficial location, high level
of oxygenation, and high cell turnover rate. A pooled analysis of
seven studies revealed that thyroid cancer was induced even by
low doses of brief external γ-radiation in childhood, but rarely
developed after exposure in adulthood. Data from the atomic
bomb survivors underline the strong modifying effect of age at
exposure, with no excess risk seen in individuals older than 20
years. During the first 14 years after the Chernobyl accident,
∼1800 thyroid cancers were diagnosed in the three most contamin-
ated countries among children younger than 15 years, whereas only
three or four childhood thyroid cancers were registered annually
in the same area before the accident. No increased thyroid cancer
as a consequence of the Chernobyl accident has been identified in
adults.
The major concern regarding medical use of ionising radiation
has been the possibility that thyroid examinations or treatments
using radioiodine cause thyroid cancer. The annual number of
thyroid examinations using radioiodine is currently five per 1000
individuals in the western world. Patients treated with 131I for
hyperthyroidism are almost entirely adults and no increased risk
of thyroid cancer is seen among these patients. It is also likely that
the doses, ranging from 100 to 300 Gy, received by the thyroid
gland induce cell killing instead of carcinogenic transformation.
Nuclear workers. Many studies have been carried out of cancer
among nuclear industry workers. Most of the exposures to these
workers were in line with international standards. In contrast,
many workers at the Mayak plant in Russia received high doses
over a protracted period, and raised (but poorly quantified) risks
have been seen for several types of cancer in this group. Some of
the worker studies have been limited by relatively small popu-
lation sizes and/or short follow-up periods. The larger studies
include a combined analysis of ∼95000 workers in Canada, the
US and the UK, and cohorts of >100000 nuclear workers in Japan
(although with a short follow-up) and the UK. Most of the
analyses have looked only at mortality. There has been some vari-
ation in the findings, which may be due in part to low statistical
precision. However, mortality has often been lower than in the
general population, due probably to factors associated with
selection into and continuation of employment. The larger studies
have tended to indicate an increasing trend in leukaemia risk with
increasing dose, whereas the evidence for a dose-related increase
in solid tumour risks has generally been less. However, the con-
fidence limits for these trend estimates have been relatively wide,
and encompass risks extrapolated from the Japanese atomic-bomb
survivors as well as a range of values, both higher and lower. More
precise information will be obtained from an ongoing inter-
national collaborative study of cancer risk in nuclear industry
workers.
At present, the findings from these studies do not indicate the
need to modify current radiation protection measures for workers.
Populations living near nuclear installations. Various studies
have been carried out of cancer rates in the vicinity of nuclear
installations in recent years, mostly in Western Europe and North
America. Doses to populations around these installations were
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generally several orders of magnitude lower than those to persons
living near the Techa River in Russia at the time of high dis-
charges from the Mayak plant. There is evidence of raised cancer
risks in this latter group, although quantification is difficult.
There does not appear to have been a general increase in rates
of adult cancers around nuclear installations. Some, but not all,
studies have indicated increased rates of childhood cancers and
particularly childhood leukaemia. The evidence for such increases
has tended to be strongest in the vicinity of nuclear reprocessing
plants; in particular, Sellafield and Dounreay in the UK and, to a
lesser extent, La Hague in France. Interpretation of these studies
has been hindered in part by small numbers of cases and by the
ecological (correlation) study design used in many instances.
Assessments of radiation doses to those living near these installa-
tions do not suggest that the raised childhood leukaemia risks can
be explained on the basis of radioactive discharges. Case–control
studies generally do not demonstrate clear links with habits that
might give rise to enhanced environmental exposures. A case–
control study around Sellafield suggested a link between child-
hood leukaemia and paternal occupational radiation exposure
prior to conception. However, this has not been replicated in
larger studies elsewhere, and may have been a chance finding.
Non-radiation factors such as population mixing have been men-
tioned as possible explanations for the raised risks, but it is unclear
whether these factors could explain all the results.
At present, specific actions are not indicated over and above
existing guidelines on radiation exposures to members of the
public. However, continued monitoring of environmental radio-
activity and cancer rates around nuclear installations is desirable.
Power lines and cancer. Power lines produce extremely low
frequency (ELF) electromagnetic fields in range of 50–60 Hz.
Electric fields do not reach people inside houses, but magnetic
fields go through most materials and cause an additional exposure
higher than the typical background field (about 0.1 µT) up to a dis-
tance ∼50 metres from the power line, depending on the voltage
and wire configuration. Health effects on humans related to this
non-ionising type of radiation have been investigated in epidemio-
logical studies for over two decades.
The first report of an association between childhood cancer and
power line exposure was published in 1979, and after that at least
24 studies on the same topic have been published. There have
been two meta-analyses published lately that both suggest a
significant 1.7–2.0-fold excess of childhood leukaemia in the
extremely rarely existing fields above 0.3 or 0.4 µT. The excess
may be attributable to patient selection and publication bias, and a
plausible biological mechanism is not known.
It appears on the basis of studies with large numbers of cancer
cases that there is no excess risk of cancer among adults living
close to power lines, but the possibility of an association between
some cancers and exposures to ELF magnetic fields is suggested
by some occupational studies.
IARC classified ELF magnetic fields as possibly carcinogenic
to humans (Group 2B) in its evaluation [14], while ELF electric
fields were considered not to be classifiable as to their carcino-
genicity to humans (Group 3). This evaluation only considers the
likelihood of an association, but does not take into account the
magnitude of the possible risk to individuals nor the population
attributable risk. The results of epidemiological studies suggest
that appreciable magnetic field effects, if any, are concentrated
among relatively high and uncommon exposures.
Cellular telephones and cancer. The use of cellular phones and
possible adverse health effects related to their use, attract much
attention. Reports of brain tumour excesses occurring among phone
users, case stories in the press and reports on thermal as well as
magnetic effects on exposed tissue hypothesised to stimulate
tumour growth, combined with the explosion in subscribers
to cellular phones, raise public concern. The radiation from the
cellular phones is characterised as non-ionising, alongside radar,
microwave ovens and electrical wiring configuration. The radio
frequency signals emitted from the devices range between 450
and 2200 MHz, i.e. in the microwave region of the electro-
magnetic spectrum.
A comprehensive review of the epidemiological literature was
recently carried out by Boice and McLaughlin [15] and published
by the Swedish Radiation Protection Authority. They conclude,
after a review of nine major studies (two cohort studies on cancer,
three hospital based case–control studies, one incidence popula-
tion based case–control study and two prevalence based case–
control studies), that no significant association is present for brain
tumours and use of cellular phones, irrespective of duration of use,
type of phone (digital or analogue), tumour morphology or lateral-
ity. The follow-up, however, is short, and even if relative risks are
unlikely to exceed 1.3 it is important to monitor this exposure to
exclude the possibility of any long-term effects. On the other
hand, no biological mechanism supports a causal relation and there
is no evidence of adverse effects on laboratory animals.
There are public health programmes that could 
prevent cancers developing or increase the 
probability that a cancer may be cured
Early detection is an important factor in reducing the death rate
from cancer, whether it is achieved by personal actions or through
participation in organised public health programmes. Awareness
of different visual body signs or symptoms that could easily be
observed by anyone and that are possibly related to cancer is
important. It is unequivocally established that cancer survival is
better for early, localised disease than for the later stage, advanced
forms of the disease. Thus, the earlier in the process that a cancer
can be diagnosed and treated then the better this is for the patient.
Potential symptoms of cancer should not be ignored, but should
serve as a clear warning for the individual to consult his or her
doctor for advice. The signs and symptoms described in Table 10
are not specific for cancer. When any one is present, the individual
should see a doctor.
Much effort has gone into cancer screening and the develop-
ment of methods for finding cancers at an earlier stage in their
development and increasing the prospects of a cure. It is possible
to make recommendations based on the available evidence.
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8. Women from 25 years of age should 
participate in cervical screening. This should 
be within programmes with quality control 
procedures in compliance with European 
Guidelines for Quality Assurance in Cervical 
Screening.
In many developing countries, the uterine cervix is one of the most
prevalent sites for cancer, comprising ∼25% of all female cancers.
In industrialised populations, the disease is less common. In east-
ern and central European populations, the annual age-adjusted (using
the World Standard Population as reference) incidence rates for
invasive disease are 15–25 per 100000 women. In the Nordic
countries, the annual incidence was 15–30 per 100000 women
before the start of large-scale mass screening programmes.
The effectiveness of screening for cervical cancer has never
been demonstrated in a randomised trial. There is, however, suf-
ficient non-experimental evidence showing the efficacy of screen-
ing using a cervical smear (Pap) test performed every 3–5 years.
This is based on case–control and cohort studies and on time
trends and geographical differences associated within screening.
The largest of these is the collaborative study co-ordinated by the
IARC which showed that eradication of the disease is an unreal-
istic goal and that maximal protection after a negative smear is
about 90%, which remains roughly the same during several years
after the test. This conclusion is in agreement with the results of
studies on the natural history of the disease, which have shown
that most preinvasive lesions progress to frankly invasive cancer
only over several years.
The effects are somewhat smaller at a population level. In some
of the Nordic countries, the reduction was about 80% in women
in the age groups exposed most intensively to screening. In the
mid-1980s, after several years of organised screening, the overall
incidence was 5–15 per 100000 woman-years.
Cervix cancer screening should be offered to all women over
25 years. There is limited evidence of benefit from screening in
women aged over 60 years, though the likely yield of screening
is low in women over age 60 since the incidence of high-grade
cervical lesions declines after middle age. Screening this age
group is associated with potential harms from false-positive results
and subsequent invasive procedures. Stopping screening in older
women is probably appropriate among women who have had
three or more consecutive previous (recent) normal Pap smear
results. Yield is also low after hysterectomy, which leaves some
cervical tissue, and there is scant evidence to suggest that screen-
ing produces improved health outcomes.
An organised programme consists of several essential elements.
Defining the population to be screened is important. Personal
invitation is the single most important means of attaining high
attendance, especially when it is combined with effective infor-
mation through the mass media. Free service has also been shown
to improve attendance. Quality assurance of all steps of the pro-
cess, monitoring and constant evaluation of the proportion of
cancer detected, false positives and false negative readings, are
mandatory. Near maximal effectiveness is achieved by an organ-
ised programme with high coverage, in which screening is initi-
ated at the age of 25 years and is repeated at three- or five-year
intervals until the age of 60. Extension of this approach should
be considered only if maximal coverage has been attained, the
resources are available and the marginal cost-effectiveness of the
recommended changes has been evaluated. European  Guidelines
for Quality Control in Cervix Cancer Screening have been
developed and are widely followed in Europe.
Infection with certain strains of HPV, generally acquired sexu-
ally, is the most important risk factor for cervical cancer. With the
use of (modern) HPV detection methods >90% of squamous cell
cervical cancer and 75–85% of high-grade cervical intraepithelial
neoplasia (CIN) lesions have detectable HPV DNA. Given the
implication of HPV infection in cervical cancer, detecting HPV
could represent an appealing screening method. A study of 2009
women having routine screening in England and Wales, showed
that 44% of CIN lesions of grade 2/3 detected had negative cyto-
logy and were found only by HPV testing (for types 16, 18, 31 and
33): a further 22% were positive for HPV but demonstrated only
borderline or mild cytological changes. However, 25% of CIN
grade 2/3 lesions were not detected by the four HPV tests.
Routine HPV testing for cervical cancer screening is an import-
ant research topic at present as HPV infection is very common in
women <30 years old, and what matters are those women over the
age of 30 with a HPV infection that persists over a long period of
time. HPV testing is still to be evaluated to find the role it could
play in cervical cancer screening. It has the potential to become an
important test in detecting cervix lesions in future and should be a
current research priority.
9. Women from 50 years of age should 
participate in breast screening. This should be 
within programmes with quality control 
procedures in compliance with European Union 
Guidelines for Quality Assurance in 
Mammography Screening.
Mammography can detect breast tumours at a clinically undetect-
able stage. The results of the early randomised trials of mammo-
graphic screening demonstrated the value of this technique and
led to the introduction of organised national programmes of
Table 10. Cancer’s early warning signs
See a doctor if you notice:
A lump
A sore which does not heal (including in the mouth)
A mole which changes in shape, size or colour
A new skin lesion which appears and continues to grow
Abnormal bleeding
See a doctor if you have persistent problems, such as:
A persistent cough
Persistent hoarseness
A change in bowel or urinary habits
An unexplained weight loss
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screening in several countries in 1986–1988. Reports from seven
trials involving over half a million women subsequently indicated
a reduction in mortality from breast cancer of ∼25% in women
invited to be screened. The reduction of mortality in those actually
attending screening is about one third.
There is now considerable evidence that breast cancer screening
with mammography is effective in reducing mortality from breast
cancer. An overview of the Swedish trials reported relative risks
of death of 0.71 in the group randomised to receive an offer of
screening, with 95% CI 0.57–0.89 for women aged 50–59 years at
entry. Results for women ages 60–69 were almost identical. When
applied to a population, a well-organised programme with a good
compliance should lead to a reduction in breast cancer mortality of
at least 20% in women aged over 50.
The value of screening women aged <50 years is uncertain. No
trials have had large enough statistical power to analyse these
women separately. What recommendations should be made for
mammographic screening of women aged between 40 and 49 is an
important question that cannot currently be answered; over 40%
of the years of life lost due to breast cancer diagnosed before the
age of 80 years are attributable to cases presenting sympto-
matically at ages 35–49 years, frequently an age of considerable
social responsibility.
Swedish workers have recently conducted an overview of four
of their trials. The conclusions indicate that the benefit of breast
screening, in terms of a reduction in breast cancer mortality of
21%, persisted for a median time of 15.8 years. In addition to this
overview, two working groups have been convened. A working
group of the IARC met in Lyon on 5–12 March 2002 and con-
sisted of 24 experts from 11 countries. The quality of the seven
trials was assessed and it was concluded that screening by
mammography reduced mortality from breast cancer in women
of 50–69 years of age. In women who participated in screening
programmes this reduction was estimated at 35%. For women of
40–49 years, evidence for a reduction in mortality was too limited
to reach a conclusion. The evidence is insufficient to recommend
performing routine breast self-examination as a method of screen-
ing.
Forty years of clinical trials, the contribution of hundreds of
scientists and health workers and the dedication of hundreds of
thousands of women to participate in studies lasting for decades
has resulted in adequate evidence to support the efficacy of mammo-
graphic screening for breast cancer, which now allows its transfer
to the arena of public health care. Doctors and women should be
assured that participation in organised screening programmes
with high quality control standards is of benefit, provided appro-
priate investigation and treatment is available. European Guide-
lines for Quality Control in Mammographic Screening have been
developed and are widely employed throughout Europe.
Special efforts should be made to encourage screening among
the more deprived members of communities. It is important not
to over-emphasise the benefit of screening, and to appreciate that
mammographic screening is but one step in the total care of
women with the disease. As had been shown by long-term
established programmes in the UK, Sweden, Finland and The
Netherlands recognition of the importance of the multidisciplin-
ary team in the assessment of mammographic abnormalities
spread into the symptomatic sector leading to the development of
integrated multidisciplinary breast care centres. Staffed by dedi-
cated surgeons, radiologists and pathologists working alongside
breast care nurses, counselling and other support personnel, these
centres offer the necessary care for women with breast cancer.
10. Men and women from 50 years of age 
should participate in colorectal screening. This 
should be within programmes with built-in 
quality assurance procedures.
The identification of a well-determined premalignant lesion, the
adenomatous polyp, together with the good survival associated
with early disease, make colorectal cancer an ideal candidate for
screening. In the past quarter century, progress has been made in
our ability to screen patients for colorectal cancer or its precursor
state, using advances in imaging and diagnostic technology.
Faecal occult blood guaiac test cards were first employed in the
1960s, the flexible sigmoidoscope was introduced in the mid-
1970s to replace the rigid sigmoidoscope that had been first intro-
duced in 1870, and colonoscopy has been available since 1970.
Four randomised trials have examined annual or biennial
screening with faecal occult blood testing (FOBT), while there are
only data available regarding sigmoidoscopy and colonoscopy
from observational studies, with little yet from randomised trials.
There is evidence from these randomised trials to support the use
of FOBT, with a reduction in colorectal cancer mortality of ∼16%
(95% CI 9% to 22%) from a meta-analysis [27% reduction (95%
CI 10% to 43%) among those screened]. The proposed screening
interval is 2 years, though it has been judged that yearly examina-
tions are cost-effective.
Flexible sigmoidoscopy is an alternative or complementary
method of screening whose efficacy has been consistently demon-
strated in observational studies. The higher sensitivity of colon-
oscopy over FOBT suggests that colonoscopy is more effective.
A large randomised trial of sigmoidoscopy is underway which
should have results in 2005 or 2006.
Despite the accumulating evidence showing that screening for
colorectal cancer is worthwhile, most citizens of developed coun-
tries have not been screened for colorectal cancer by any means.
While this situation persists the chance is being missed to prevent
about one quarter of the 138000 colorectal cancer deaths which
occur each year in the European Union. Special efforts are
required against colorectal cancer which is now the most common
malignant disease in the population of the European Union.
11. Participate in vaccination programmes 
against hepatitis B virus infection.
About 18% of human cancers worldwide are currently attributable
to persistent infections with viruses, bacteria or parasites. In the
European Union this fraction is about 10%, and it is chiefly
accounted by four cancer sites or types, namely cancer of the
cervix uteri, liver, stomach and some haemo-lymphopoietic
tumours. Knowledge about the role of infectious agents in the aeti-
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ology of several cancer types has rapidly expanded in the last 30
years, after major improvements were made in the detection of
markers of chronic infection. Contrary to former beliefs, antibac-
terial and antiviral treatments, as well as vaccination programs,
represent an important tool against cancer.
The four major cancer sites or types that have been linked to
infectious agents (Figure 7) will be discussed below, with special
reference to current opportunities for prevention in the European
Union countries.
Every year ∼25000 women in the European Union develop
cervical cancer. A dozen types of HPV have been identified in
99% of biopsy specimens from cervical cancer worldwide, and in
Europe HPV 16 has been reported in 56% of over 3000 cervical
cancer specimens. Five HPV types (HPV 16, 18, 31, 33, 45) account
for >85% of European cervical cancer specimens. In control
women, the prevalence of the indicated HPV types is several
dozen-fold lower. There is no effective medical treatment against
HPV; however, very sensitive and specific tests for the detection
of HPV DNA in cervical cells have become available. There is
sufficient evidence for recommending HPV testing among women
who show borderline or low-grade cytological abnormalities.
Additionally, HPV testing improves the follow-up of women who
have been treated for CIN lesions and, pending results of ongoing
trials, may offer a more sensitive alternative to cytology in
primary cervical cancer screening.
A prophylactic vaccine, based on late (L) 1 HPV 16 proteins,
has been shown to be safe, highly immunogenic and efficacious in
preventing persistent HPV infections in a trial of 1523 HPV 16-
negative young women in the USA. A multivalent vaccine against
the most common oncogenic HPV types may thus ultimately
represent the most effective way to prevent cervical cancer world-
wide, alone or in combination with screening. Vaccination would
benefit women who do not attend screening programs in the Euro-
pean Union and, if combined with current screening programs, it
would allow substantial savings (i.e. less frequent screening tests,
fewer treatments, etc.).
Every year ∼30000 new cases of liver cancer are recorded in the
European Union. Upward trends in incidence and mortality rates
have been seen in the last two decades, in men in France, Germany
and Italy. Chronic infection with hepatitis B virus (HBV) and
HCV accounts for the majority of liver cancer cases in Europe. In
a large case-series of liver cancer from six European liver centres
only 29% of 503 liver cancer patients had no marker of either
HBV or HCV infection.
An effective vaccine against HBV has been available for 20
years now. Several countries in the European Union (e.g. Den-
mark, Finland, Ireland, The Netherlands, Sweden and the UK)
do not perform routine vaccination against HBV in children, on
account of the low prevalence of HBV infection in the general
population (http://www.who.int/), whereas other countries (e.g.
Belgium, France, Germany) report coverage below 50%. There is
scope for reconsidering national policies regarding universal
vaccination against HBV since selective vaccination of high-risk
groups rarely works, and travelling and migration facilitate the
mixing of high- and low-risk populations. Although infection with
HBV in young adulthood (typically through sexual intercourse or
contaminated needles) carries a much lower risk of chronic hepat-
itis and liver cancer than infection at birth or during childhood, it
frequently induces acute hepatitis.
HCV represents an increasing problem in several areas of the
European Union (especially Italy, Greece and Spain) and in some
population groups, notably intravenous drug users. A vaccine is
not yet available, and the effectiveness of treating all HCV RNA-
positive individuals with pegylated interferon-2α with or without
ribavirin is still under evaluation. Hence, the prevention of HCV
infection relies for the moment on a strict control of blood and
blood derivatives and avoidance of use of non-disposable needles
in medical and non-medical procedures (e.g. acupuncture, tattoo-
ing, etc).
Helicobacter pylori (Hp) is associated with an ∼6-fold increased
risk of non-cardia gastric cancer. Out of ∼78000 new cases of
gastric cancer every year in the European Union some 65% may
be attributable to Hp (assuming an Hp prevalence of ∼35% in the
general population). The current therapy of Hp infection, based on
the use of proton-pump inhibitors and antibiotics, is efficacious
but poor patient compliance, antibiotic resistance and recurrence
of infection complicate the issue. Furthermore, although treatment
of Hp infection can induce regression of gastric lymphoma, it
has not yet been shown to reduce gastric cancer risk. Various
approaches have been followed in the development of vaccines
against Hp based on the use of selected Hp antigens, notably urease,
the vacuolating cytotoxin (VacA), the cytotoxin-associated
antigen (CagA) and the neutrophil-activating protein (NAP).
Unfortunately, the natural history of Hp infection and the charac-
teristics of an effective anti-Hp immune response are still poorly
understood. Pharmaceutical companies seem to be reluctant to
invest in the long and uncertain process of developing a vaccine
Figure 7. Cancer of the cervix, liver, stomach and haemo-lymphopoietic 
system as a percentage of all cancer diagnoses in both sexes in the 
European Union, 2000. Source Ferlay et al., 2000.
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against Hp, an infection perceived as declining and amenable to
medical treatment.
The fourth group of cancers where infectious agents are known
or suspected to play a major role is haemo-lymphopoietic tumours
[i.e. non-Hodgkin’s lymphomas (NHL), HD and leukaemias]—
a total of ∼104000 new cases per year in the European Union.
Certain viruses [i.e. Epstein Barr virus (EBV), human immuno-
deficiency virus (HIV), human-T-cell leukaemia/lymphoma virus
1, Herpes simplex type 8 and HCV] and Hp account for an ill-
defined proportion of NHL and HD. Childhood leukaemias may
also be linked to one or more not yet identified infectious agents.
As for Hp and gastric lymphomas, treatment of HCV has led to the
regression of some extra-nodal NHL. Highly active antiretroviral
therapy (HAART) has had a favourable impact on the occurrence
of Kaposi’s sarcoma, but not as yet of NHL, in HIV-infected
patients. Recognising and treating infections linked to haemo-
lymphopoietic tumours is a priority in the European Union, on
account of the steady increase in the number of cases and high-risk
individuals (e.g. iatrogenically immuno-suppressed and HIV-
positive subjects).
In conclusion, infectious agents account for a substantial frac-
tion of cancers in the European Union. For the moment, priorities
are the expansion of immunisation programs against HBV and the
inclusion of HPV testing in cervical cancer screening programs.
Vaccines against cancer-causing infectious agents are, however,
one of the most promising ways to prevent or even cure some
important tumours. Because of the enormous cost of vaccine
development, public–private partnerships [e.g. the Global Alliance
for Vaccines and Immunisation (GAVI) for developing countries]
should be actively pursued in the European Union, especially with
respect to the development of vaccines against HCV and Hp.
Additional items considered
The committees discussed a number of other issues in cancer
epidemiology and cancer control and decided that the situation
was not so certain that any recommendation could be made with a
convincing probability of success in reducing cancer risk. Issues
considered included chemoprevention, exogenous hormones and
screening for other forms of cancer.
Chemoprevention
β-carotene. While observational epidemiological studies have
consistently shown that β-carotene is associated with decreased
cancer risk, particularly of lung cancer, findings of seven ran-
domised trials testing the effect of β-carotene supplementation on
cancer incidence and mortality generally have not been support-
ive. Two of these trials even suggested the possibility of harmful
effects.
Two large trials of β-carotene conducted among persons at
average risk of cancer found no statistically significant benefit or
harm associated with β-carotene supplementation [16, 17]. Two
other large trials tested β-carotene among persons at high risk of
cancer [18, 19]. One reported a statistically significant (18%)
increase in lung cancer incidence after 5–8 years of treatment with
β-carotene among male Finnish smokers [18]. Another, which
used a combination of β-carotene and retinol, reported a statistic-
ally significant (28%) increase in lung cancer incidence among
American smokers, former smokers and asbestos workers [19].
Only one large trial, which tested a combination of β-carotene,
vitamin E and selenium in a poorly nourished Chinese population,
found that after 5 years, the treated group experienced a statistic-
ally significant (9%) reduction in total mortality, primarily as a
result of a statistically significant (21%) lower stomach cancer
mortality rate [20]. The (indirect) evidence that β-carotene may
protect from stomach cancer comes from the randomised, controlled
double-blinded chemoprevention trial in subjects with gastric dys-
plasia in an area with a very high gastric cancer risk in Columbia.
Gastric biopsy taken at baseline was compared with those taken at
72 months. Treatment with 30 mg β-carotene resulted in a statistic-
ally significant increase in the frequency of regression of preneo-
plastic lesions of the stomach [relative risk (RR) = 5.1, 95% CI
1.6–14.2] [21]. One small trial of 1805 people with previous
non-melanoma skin cancer that tested treatment with β-carotene
(50 mg/day) to reduce the occurrence of new skin cancer did not
find any effect of this intervention [22].
It can be concluded that there is evidence at present that β-carotene
supplements have no value as cancer chemoprevention agents and
cannot be recommended for use in the general population in this
context.
Vitamins A, C and E. In all trials in which the preventive effects
of these vitamins have been studied, they were used in different
combinations and therefore it is impossible to assess the effect of
each of these micronutrients separately.
No significant effects on mortality rates were observed for supple-
mentation with combinations of retinol and zinc [20] or β-carotene
and vitamin A [19]. Supplementation with ascorbic acid (1 g twice
per day) was associated with increases in the rates of regression of
dysplastic lesions in the stomach [odds ratio (OR) = 5.0; 95% CI
1.7–14.4] [21], whereas in a trial in Linxian (China) supplementa-
tion with vitamin C and molybdenum had no effect on overall and
cancer mortality [20].
In the study in Linxian, the intervention group receiving supple-
mentation with vitamin E, β-carotene and selenium experienced
a statistically significant (9%) reduction in overall mortality
and 13% reduction in cancer mortality, which was mainly due to
lower stomach cancer rates (OR = 0.79; 95% CI 0.64–0.99) [20].
In the α-Tocopherol, β-Carotene Cancer Prevention Study Group
[18] trial α-tocopherol had no apparent effect on total and cancer
mortality.
It can be concluded that there is no evidence at present that vita-
min A, ascorbic acid or α-tocopherol supplements have value as
cancer chemoprevention agents and they cannot be recommended
for use in the general population in this context.
Selenium. In three large randomised placebo-controlled trials,
selenium supplementation was given either alone [23] or with
other elements [20, 24].
Clark et al. [23] carried out a study in the USA on 1312 subjects
to test whether selenium supplementation could reduce the inci-
dence of non-melanoma skin cancer. Although no benefit was
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found for skin cancer, the group receiving the supplement had
statistically significant reductions of ∼40% and 50% in overall
cancer incidence and cancer mortality, respectively. Based on
these findings, there is a large randomised trial of selenium and
prostate cancer prevention on-going.
The other two studies were conducted in Linxian, China. In the
smaller study multivitamin supplements containing selenium was
randomly assigned to 3318 people with pre-existing oesophageal
dysphasia. At the end of a 6-year intervention period the group
receiving the supplement had statistically non-significant reduc-
tion of 7% in total mortality and 8% oesophageal/gastric cardia
cancer mortality [24]. In the larger Linxian trial, 29584 par-
ticipants were assigned to receive four combinations of different
nutrient supplements for 5 years. The group receiving the supple-
ment with selenium, β-carotene and vitamin A had a statistically
significant reduction of 9% in all cause mortality and 13% in
cancer mortality. In these two Chinese studies it is impossible to
disentangle the effect of selenium from effects of other micro-
elements [20].
It can be concluded that at present there is at most weak evi-
dence that selenium supplements have value as cancer chemo-
prevention agents and they cannot be recommended for use in the
general population in this context.
Fibre. In five randomised trials, dietary supplementation with
wheat bran or other types of fibre did not affect the rate of recur-
rence of colorectal adenomas. Two studies tested the effect of
dietary counselling to reduce fat consumption and increase fibre
intake [25, 26]. In one study the subjects in the intervention group
were advised to increase fat intake and take wheat-bran supple-
ment [27] and two studies tested purely the effect of fibre
supplements [28, 29].
The results of the Toronto Polyp Prevention Trial [25]
(randomised, not blinded) suggest that there was no significant
difference in polyp recurrence between persons assigned to low
fat/high fibre diet and those following a normal western diet. The
ratio of cumulative incidence rates was 1.2 (95% CI 0.6–2.2)
[25]. In a randomised (not blinded) control trial in which the inter-
vention group was assigned to the low fat, high-fibre (18 g per
1000 kcal) and high fruit and vegetable diet, no difference was
observed in recurrence rate of colorectal adenomas (and large
adenomas) between intervention and control group, who followed
their usual diet. The unadjusted risk ratio was 1.00 (95% CI 0.90–
1.12) [26].
In the Australian randomised (not blinded) trial of intake of
fat, fibre and β-carotene to prevent colorectal adenomas there was
no significant prevention of new adenomas in any of treatment
groups [27]. In a double-blind randomised study, a dietary supple-
ment of wheat-bran fibre had no statistically significant effect
against recurrent colorectal adenoma. The multivariate adjusted
OR for recurrent adenomas in the high-fibre (13.5 g per day)
group compared with the low-fibre (2 g per day) group was 0.88
(95% CI 0.70–1.11; P = 0.28); and the OR of recurrence according
to the number of adenomas in high-fibre group compared with the
low-fibre group was 0.99 (95% CI 0.71–1.36; P = 0.93) [28].
In a randomised controlled study that tested the protective
effects of supplementation with fibre (3.5 g ispaghula husk) and
calcium (2 g daily) on colorectal adenomatous polyp recurrence,
the adjusted OR for recurrence in the fibre treatment group was
1.67 (95% CI 1.01–2.76; P = 0.42). The OR associated with the
fibre treatment was significantly higher in participants with base-
line dietary intake above the median than in those with intake
below the median (interaction test, P = 0.028) [29].
It appears from the results of these randomised trials that sup-
plementation with fibre does not affect the risk of the recurrence
of colorectal polyps. The evidence of a protective effect of fibre
against colorectal cancer is purely observational and the use of
fibre cannot be recommended for the general population at the
present time.
Calcium. In a randomised double-blind study involving 913
patients, Baron et al. [30] observed that calcium supplementation
(1200 mg of elemental calcium daily) moderately reduced the
risk of recurrence of adenomatous polyps of the large bowel. The
adjusted risk ratio for any recurrence of adenoma with calcium
compared with placebo was 0.85 (95% CI 0.74–0.98, P = 0.03).
The adjusted ratio of the average number of adenomas in the
calcium group to that in the placebo group was 0.75 (95% CI
0.60–0.96, P = 0.02). The effect of calcium was independent of
initial dietary fat and calcium intake [30].
The randomised double-blind 3-year intervention study by
Hofstadt et al. [31] showed that a mixture of calcium and anti-
oxidants had a beneficial effect on adenoma recurrence, though not
on adenoma growth; the effects of calcium could be disentangled
from those of antioxidants. In the study of Bonithon-Kopp et al.
[29], which tested the efficacy of fibre and calcium supplements in
prevention of colorectal neoplastic polyp recurrence, the rate of
recurrence was statistically non-significantly decreased in the
calcium (2 g daily) treatment group. The adjusted OR for recurrence
was 0.66 (95% CI 0.38–1.17; P = 0.16)
The evidence suggesting that calcium supplementation decreases
risk of colorectal adenomas is not yet sufficient to recommend its
use to the general population as a strategy to prevent colorectal
cancer.
Nonsteroidal anti-inflammatory drugs (NSAID). Numerous obser-
vational epidemiological studies have found that long-term users
of aspirin or other NSAIDs have a lower risk of colorectal adeno-
matous polyps and colorectal cancer than non-users. Randomised
clinical trials have confirmed that two NSAIDs, the prodrug sulin-
dac and selective cyclooxygenese (COX)-2 inhibitor celecoxib,
effectively inhibit the growth of adenomatous polyps and cause
regression of existing polyps in patients with familial adeno-
matous polyposis (FAP) [32, 33]. Less promising are results on
the far more common sporadic adenomatous polyps. Treatment
with sulindac did not result in regression of sporadic adenomas
[34] or doses required to achieve the effect may cause toxicity,
which outweighs the benefits of treatment [35].
Despite some positive results obtained in studies in humans and
coupled with biological plausibility [36], the efficacy of long-term
NSAIDs prophylaxis against colorectal cancer, and other cancers,
994
remains unproven. Recommendations regarding the use of NSAIDs
for prevention of colorectal cancer, except probably the use of
celecoxib or sulindac for control of the growth of colorectal
adenomas among patients with FAP, appears to be premature at
the present time.
Tamoxifen. Five trials have now reported on the use of tamoxifen
and raloxifen for prevention of breast cancer [37–41]. Four trials
compared 20 mg tamoxifen daily for at least 5 years with placebo
[42]. One trial compared two doses of raloxifen (60 mg or 120 mg)
with placebo [41]. Cuzick et al. [42] report an overview of the
main outcomes of these prevention trials and adjuvant trials in
which tamoxifen treatment was given for at least 3 years with
doses of 20–40 mg. The combined data from tamoxifen preven-
tion trials supported a reduction in breast cancer incidence by 38%
(95% CI 28% to 46%; P <0.001). The adjuvant studies and the
raloxifen trial showed greater reductions (46% [95% CI 29% to
63%] and 64% [95% CI 44% to 78%], respectively). There was no
effect for breast cancers negative for oestrogen receptors (ER), but
ER-positive cancers were decreased by 48% (95% CI 36% to
58%). Rates of endometrial cancer were increased in tamoxifen
prevention trials (RR = 2.4, 95% CI 1.5–2.6). No increase has
been seen with raloxifen. Venous thromboembolic events were
increased in all tamoxifen studies and with raloxifen.
The evidence now clearly shows that tamoxifen can reduce the
risk of ER-positive breast cancer. However, high rates of side-
effects do not permit a recommendation of the prophylactic use of
tamoxifen in healthy women based on current evidence.
Exogenous hormones
Oral contraceptives. Over the last decade, several epidemio-
logical studies have been published on the oral contraceptives
(OC) and cancer risk issue. These studies were reviewed in June
1998 by an IARC Working Group, and are summarised in the
IARC monograph 72 [43].
A collaborative reanalysis of individual data on 53297 breast
cancer cases and 100239 controls indicated that there is a moder-
ate excess risk for this disease among current or recent OC users,
which tends to level off in the few years after stopping use. OC use
has also been found to be positively associated with cervical
cancer risk in HPV-positive women. Conversely, OC (with the
exception of the currently not used sequential type) reduce the risk
of endometrial cancer. Further, data on ovarian cancer indicate a
long lasting protection from OC use, which may well be evident
up to 20 years after cessation. Several studies have suggested an
inverse relation between use of OC and risk of colorectal cancer,
but no association with duration of use was observed. An increased
risk for OC users of hepatocellular carcinoma is considered as
established.
The main established evidence on the OC and cancer issue can
be summarised as follows:
• There is a small increased risk of breast cancer among current
users, but not among former users who have ceased for 10 or
more years.
• OC lower the risk of endometrial and ovarian cancer, and the
protection seems to persist after cessation of use.
• A reduced risk of colorectal cancer among OC users is pos-
sible, but this issue is still open to discussion.
• OC are related to increased risk of cervical cancer and liver
cancer, but the public health importance of these associations
is small in developed countries.
• OC have been used for 40 years, and the formulations have
been modified repeatedly. It is therefore difficult to propose
further modifications that may appear favourable on the risk of
selected diseases without increasing the risk of other side-
effects.
Hormonal replacement therapy. Hormonal replacement therapy
(HRT) has been reported to increase breast cancer risk. In a col-
laborative reanalysis of individual data from 51 epidemiological
studies including >52000 women with breast cancer and 108000
without breast cancer, breast cancer risk increased by ∼2.3% per
year of use, but dropped after cessation of use. There is evidence
that combined oestrogen–progestogen HRT may be associated
with higher risk of breast cancer compared with unopposed
oestrogens. In contrast, unopposed oestrogen use, but not com-
bined oestrogen–progestogen treatment, has been strongly related
to endometrial cancer risk in observational studies.
HRT has also been reported to be positively associated with
ovarian cancer risk, and inversely to colorectal cancer risk.
Important information on cancer risk in users of combined
estrogen and progestogen HRT comes from the Women’s Health
Initiative (WHI), a randomised primary prevention trial including
8506 women aged 50–70 years treated with combined HRT and
8102 untreated women. The combined treatment group was
closed in May 2002, whereas an additional oestrogen only group
is still ongoing (as of November 2002). With respect to breast
cancer, no difference in risk was evident for the first 4 years after
starting treatment, but an excess risk was evident thereafter. At the
7 years follow-up, 166 breast cancer cases were registered in the
treated group versus 124 in the placebo group, corresponding to a
RR of 1.24 (95% CI 1.03–1.66). Data from two other smaller ran-
domised studies are available, one Heart and Estrogen/progestin
Replacement Study (HERS) with combined oestrogen–progestogen
therapy, and one (WEST) with estrogen only. In a combined
analysis of the three randomised trials, 205 cases of breast cancer
were registered in the treated groups versus 154 in the placebo,
corresponding to an overall RR of 1.27. Since, however, this esti-
mate is heavily weighted by the WHI study, the quantitative role
of estrogen only HRT on breast cancer risk cannot be conclusively
documented.
Data on endometrial cancer are available from the WHI and the
HERS study, both based on combined therapy. Overall, 24 cases
were observed in the combined HRT groups versus 30 in the pla-
cebo groups, corresponding to a pooled RR of 0.76.
With reference to colorectal cancer, the combined analysis of
the WHI and HERS studies included 56 cases in the HRT treated
group and 83 cases in the placebo group (RR = 0.64).
Thus, with reference to HRT and cancer risk, the recent findings
of randomised trials are in broad agreement with those of observa-
tional (cohort and case–control) studies, and therefore provide
strong evidence that:
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• Combined oestrogen–progestogen HRT is associated with a
moderate excess risk of breast cancer, which becomes evident
after a few years of use. Such an increased risk appears to be
restricted to current users.
• The pattern of risk in relation to HRT use appears similar for
ovarian cancer, although data remain inadequate.
• Unopposed estrogens are strongly related, but combined HRT
is not associated to, a material excess risk of endometrial
cancer.
• HRT may have a favourable effect on colorectal cancer risk,
although the relation with duration and other time-related fac-
tors remains unclear.
• Considering also the apparently adverse effects of HRT on
cardiovascular diseases, HRT should not be recommended for
disease prevention. HRT remains indicated for short-term
symptom relief, while other treatments should be considered
for osteoporosis.
Screening for other forms of cancer
Screening has been defined as the systematic application of a test
or inquiry to identify individuals at sufficient risk of a specific dis-
order to benefit from further investigation or direct preventive
action, among persons who have not sought medical attention on
account of symptoms of that disorder. Before a screening test can
be introduced it is necessary to be able to demonstrate that the test
not only distinguishes people who will develop the disease from
those who will not, but that a remedy is available to individuals
who are judged to be screen-positive that can significantly improve
their health compared with not screening, and treating the disease
on clinical presentation in the usual way.
In assessing screening tests for cancer, a large randomised
trial is usually necessary. This would compare mortality from the
specific cancer in a group that has been screened and treated with
the corresponding mortality in an unscreened group that received
treatment only after clinical presentation. In screening programmes
that aim to detect cancer lesions at an early stage it is impossible to
determine the proportion of all of the cancers in question that
would have presented clinically over a specified period that are
detected by screening, because cancers cannot be detected without
then intervening. The outcome of screening trials is therefore
expressed as a proportional reduction in mortality from the
specific cancer and then a judgment made as to whether this is
worthwhile.
Table 11 shows the cancers and screening methods that have
been shown to be worthwhile, those that are of unknown value and
those that are known to not be worthwhile. Breast cancer screen-
ing by mammography in women aged over 50 years can reduce
mortality from the disease by ∼30%. Screening for colorectal
cancer by FOBT can reduce mortality from the disease by ∼15%.
Both rates were shown using randomised trials. Screening for
cancer of the cervix by cervical cytology has been judged to be
worthwhile (∼80% reduction in mortality from this disease),
though without evidence from randomised trials.
A difficulty with screening is that some cancer screening pro-
grammes have been introduced in the absence of evidence that
they are worthwhile, for example, prostate cancer screening, and
breast cancer screening in women aged under 50 years. It is
Table 11. Cancers and screening methods that have been shown to be worthwhile, those that are of unknown value and 





Colon/rectum Faecal occult blood
Value of screening unknown (research in progress)
Prostate Prostate specific antigen
Stomach H. Pylori testing; radiographic/endoscopic stomach examination
Colon/rectum Flexible sigmoidoscopy
Ovary CA125 and/or ultrasound
Breast Mammography in women <50; BRCA1 and 2 mutation in Jewish women
Cervix Human papilloma virus testing
Lung Spiral computed tomography (CT)
Skin cancer (Melanoma) Examination for moles
Oral cancer Examination of the mouth
Screening not worthwhile
Neuroblastoma Urinary homovanillic acid (HVA) and vanillylmandelic acid (VMA)
Lung cancer Chest X-ray
Breast Breast self-examination
Testis Self-examination (because modern treatment after clinical presentation is so effective)
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important that health authorities resist the temptation to introduce
population screening programmes until there is firm evidence of
efficacy, as judged by a reduction in mortality from the cancer in
question. The presumption of benefit should not be sufficient
grounds for introducing large scale programmes.
Sometimes an effective screening test [e.g. prostate-specific
antigen (PSA) for prostate cancer] has led to the introduction
of screening programmes in the absence of trial results showing
evidence of benefit in terms of disease prevention. Once such
services are in place they can be difficult to stop. Then existing
data should be used to try to evaluate efficacy, albeit in a less than
ideal manner.
There is a general need to continually evaluate screening ser-
vices to ensure that the performance expected from the results of
randomised trials and other relevant research can be achieved in
practice. Service provision will depend on available resources and
the burden of disease from the cancer in question in the absence of
screening.
The following cancer screening programmes should be made
generally available:
1 Screening for breast cancer by 3 yearly mammography exami-
nations for women from the age of 50 years.
2 Colorectal cancer screening by FOBT every 2 years from the
age of 50 years.
3 Cervical cancer screening by 5 yearly cervical smear exam-
inations for women from the age of 25 years.
Others should not be offered as services at all or should be part
of research programmes designed to determine their value. There
are screening tests available and being evaluated for stomach
cancer, oral cancer, nasopharynx cancer and neuroblastoma.
Screening for prostate cancer and screening for lung cancer are,
however, the subject of much recent research.
Screening for prostate cancer. At the present time there is pres-
sure to screen for prostate cancer, but implementation of screening
programmes for prostate cancer cannot be recommended based on
the available evidence. The main reason for this situation is that no
results are available from randomised trials assessing screening
for prostate cancer. These are the only methods of evaluation
which avoid bias and, in consequence, it is not known whether
screening by one of the available modalities or in combination
is effective in leading to a reduction in the mortality rate from
prostate cancer. This is a necessary prerequisite for embarking on
population screening.
Any reduction in mortality from prostate cancer due to screen-
ing, while uncertain, must be weighed against the harm from
screening diagnosis and treatment. Some men who do not need
treatment are likely to receive it. These are men destined to die of
causes other than prostate cancer. Unfortunately, at diagnosis,
men needing treatment for prostate cancer cannot be differentiated
from men who do not.
The PSA test is simple, cheap, readily available and acceptable.
PSA testing has already achieved a high penetration among men
and their physicians. To document the extent of PSA testing in the
general population at Getafe (Spain) a total of 5371 PSA test
records (1997–1999) were reviewed and testing rates estimated
per 1000 person-years. The PSA-testing rate in the general popu-
lation was 21.6/1000 person-years. In the age-group 55–69 years,
this rate was 86.8/1000 and increased to 152.6/1000 in men
>70 years. In Milan, Italy where there is no campaign publicising
or encouraging prostate cancer screening, it has been estimated
that 26.9% of men aged 40 and older and without a history of pros-
tate cancer received a PSA test in the 2-year period 1999–2000. In
men aged 50 and greater, this rate rose to 34%.
Multiple sources of data show that prostate cancer incidence
rates rose following the introduction of PSA testing. The average
age at diagnosis has fallen, the proportion of advanced stage
tumours has declined, the proportion of moderately differentiated
tumours has increased, and patterns of care have changed accord-
ingly. A decline in mortality began in the USA and other countries
in 1991. The decline in mortality is well established, but this
recent trend may only retrace an increase in mortality that imme-
diately preceded it. The descriptive epidemiology of prostate
cancer reveals many effects of the introduction of prostate cancer
screening. Although the evidence suggests increased prostate
cancer testing has yielded public health benefit, this has not yet
been shown conclusively and a decision on the value of screening
should await the results of trials. In any event, systems should
now be in place to ensure that men and physicians participating
in PSA testing participate in a programme in which the effect of
the intervention can be evaluated as best can be done given the
non-experimental nature of the intervention.
Screening for lung cancer. It has long been established that the
best way to control lung cancer is to reduce cigarette smoking in
the population, foremost through prevention, and secondarily through
smoking cessation. However, even after stopping smoking long-
term smokers remain at high risk of lung cancer. Lung cancer
when clinically diagnosed has a poor outcome with 10–16%
survival at 5 years. If the tumour is small enough to be removed
surgically, the outcome is much better, >70% for stage I tumours.
This led to speculation in the past as to whether long-term smokers
or others at high risk might benefit from earlier detection.
Low-dose spiral CT scanning can detect lung cancer at an early
stage. The Early Lung Cancer Action Project (ELCAP) demon-
strated that spiral CT was able to identify very small lung cancers
in high-risk volunteers, with a resectability rate of 96% and a pro-
portion of stage I >80%. An initial high false-positive rate was
reduced by high-resolution CT (HRCT) with a complex algorithm
of 3D reconstruction for tumour growth. Randomised trials of
spiral CT using a non-intervention control group and with lung
cancer mortality as the trial outcome are needed to determine the
value of this method of screening.
Genetics
A clearer understanding of carcinogenesis is emerging with our
rapidly expanding knowledge of genetics. At the same time there
remain issues surrounding genetics and genetic testing, which are
very important. Cancer results from a breakdown in the genetic
control of cell growth and behaviour. The study of genetic
changes associated with different types of cancer has been under-
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way for over 40 years and has become central to the diagnosis and
management of many cancers. For example, most leukaemias are
associated with specific chromosomal rearrangements that acti-
vate the genetic messages which stimulate growth of that cell type.
One of the earliest discoveries, the Philadelphia chromosome in
chronic myeloid leukaemia, was later shown to involve a trans-
location joining together pieces of chromosomes 9 and 22. This
produced an abnormal gene capable of generating a tyrosine
kinase like product. Recently, a highly effective drug designed to
block that gene product, imatinib, has been approved for clinical
use.
It is now essential for the effective management of most leuk-
aemias to have access to high quality cytogenetic diagnosis. These
techniques are being extended into the use of molecular diagnostic
techniques. A good example is detection of the characteristic
amplification of the proto-oncogene Nmyc in neuroblastoma and
her2 in breast cancer. These changes are somatic errors, mistakes
which arise in a cell in the body at some time after conception. In
almost all cases, a series of genetic errors must occur before a cell
becomes capable of uncontrolled growth and spread to other sites.
In some individuals, a genetic error in the germline that predis-
poses them to cancer affects every cell in the body. Such changes
can be inherited, resulting in families with multiple affected mem-
bers. The last decade has seen an upsurge in discoveries of the
genes that underlie these hereditary forms of cancer. The attrac-
tion of this research has been that it provides a means of more
accurate diagnosis, and in some cases allows presymptomatic
diagnosis. Any gene which, when defective, predisposes to malig-
nancy is usually a key part of an important pathway. As a result,
discovery of these genes has led to a better understanding of the
causes of common cancers.
The classic example is the APC gene on chromosome 5 which
underlies the rare dominant syndrome FAP. In most colorectal
adenocarcinomas both copies of this gene are inactive, a change
which is apparent in early adenomas. The identification of a path-
ological mutation in the APC gene, typically a frameshift mutation
distal to the catenin binding site in exon 15, is of great clinical
value as it allows accurate identification of other family members
who will need regular endoscopy and prophylactic surgery. Of
equal importance is the ability to discharge with confidence those
family members who have not inherited the defective copy of the
gene. A range of similar cancer syndromes are now amenable to
molecular diagnosis; multiple endocrine neoplasia, Von Hippel
Lindau syndrome, juvenile polyposis and neurofibromatosis
type 2 are important examples of dominant syndromes. Recessive
syndromes include Fanconi’s anaemia and Bloom’s syndrome,
both of which are examples of defective DNA repair. Provision of
diagnostic services for such disorders needs to be organised at
regional, national and sometimes supranational levels to ensure an
appropriate level of quality assurance and technical expertise.
A second and more problematic category of molecular diag-
nosis has become possible in the last decade; several genes have
been identified which, when defective in the germline, predispose
to a high penetrance form of one of the common forms of cancer.
Such patients lack the characteristic syndromic features that allow
easy targeting of molecular genetic expertise. The breast/ovarian
cancer predisposition genes BRCA1 and BRCA2 and members of
the mismatch repair gene family, such as MSH2 and MLH1 that
predispose to colorectal cancer and endometrial cancer among
others, are the classic examples of this category. These are large
genes in which many hundreds of pathological changes are pos-
sible. Distinguishing causative mutations from harmless popula-
tion variants in families with multiple affected members is a major
challenge, which is being met through international cooperation.
Methods of rapid analysis of such genes are becoming available.
In the foreseeable future it is likely that all breast, ovarian, colo-
rectal and endometrial cancers will be checked for germline muta-
tions in these and similar genes so as to better characterise the
cancer and allow more effective therapy. In the meantime, limited
diagnostic resources must be targeted at those individuals most
likely to generate a result of diagnostic value.
Mutation detection in the mismatch repair genes is best focused
on affected individuals who are part of a family that satisfies the
modified Amsterdam criteria. These were designed to identify
useful research families, but are also valuable in targeting diag-
nostic resources. Suitable individuals belong to families in which
there have been at least three cancers in people where one is a first
degree relative of the other two. For example, a woman, her son
and her brother. Provided they have colorectal cancer and/or
endometrial or gastric cancer and one had onset before 50 years of
age, there is a >90% probability that a mutation in MSH2 or MLH1
will be detected. Almost all tumours resulting from defects in
these mismatch repair genes display a characteristic instability of
the DNA microsatellite markers used in traditional genetic link-
age studies. Immunohistochemistry for the protein product of
MSH2 is also valuable as its absence is a strong indication of
mutation in the MSH2 gene. This technique is less effective for
MLH1 because a large proportion of sporadic colorectal cancers
lose expression of this protein due to a reversible suppression of
gene expression.
Mutation detection in the BRCA genes is best focused on fami-
lies where there have been at least four affected individuals in
multiple generations. Families that feature breast and ovarian
cancers, bilateral cancers in young women and male breast cancer
are all worthy of diagnostic testing. The primary problem is the
slow development of these molecular diagnostic services. Urgent
investment in laboratory facilities and staff training is needed to
prepare for the expansion of diagnostic need. It is estimated that
overall at least 5% of the common cancers other than lung cancer
have a single gene defect underlying them that would be amenable
to predictive testing and more effective prevention and therapy. In
pure health economic terms the benefits are obvious of catching
early a solid tumour allowing cure rather than prolonged palliation
of cases diagnosed later. Unfortunately, the financial benefits of
cure affect different aspects of health care to the services called
upon to deliver diagnostic genetic services. There is a willingness
of European genetics centres to integrate their work. This is threat-
ened by the need to compete in a more commercial setting and by
the patenting of genes such as BRCA1. Gene patenting can hamper
the rapid development and dispersal of diagnostic tests and is
likely to restrict fulfilment of the potential of genetic testing in
cancer prevention.
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The next phase of genetic discovery will be to identify genes
that contribute to the heritable component of the cause of cancer,
but are not sufficiently influential to account for families with a
classic pattern of inheritance of cancer. The gene CHEK2 occu-
pies a critical role in cell cycle control. Association studies within
cases of familial breast cancer have identified mutations in this
gene as being a significant risk factor in predisposition to breast
cancer. In most cases, defective function of at least one other
unidentified gene is needed to precipitate disease. Such genes,
which confer a mild to moderate increase in predisposition, are
likely to interact with environmental triggers to lead to cancer in a
proportion of people with the at risk genotype. These develop-
ments will lead to a growing list of genetic variations in the
population being identified as conveying an increased risk of
malignancy. The major challenge will be to quantify the risk
associated with such genetic variation in different environmental
settings. It is likely that a range of biases will lead to several such
associations being assigned an inappropriate significance. Large
scale population based evaluation will be needed, such as will
become possible with the new Biobank UK project, before these
moderate risk genes can be incorporated into clinical practice.
Cancer mortality trends
The total number of cancer deaths will be influenced by both the
size and the age distribution of the population. Age standardised
mortality rates have to be used to adjust for these. To measure the
effect of the third version of the European Code Against Cancer
on cancer mortality, reliable estimates are needed for the near
future, taking the recent trends in mortality and the projected
populations into account. Age standardised cancer mortality rates
and numbers of cancer deaths have been estimated for the period
2000–2015 using the most recent cancer mortality data and
statistical models.
Mortality data were obtained from the WHO database: long
time series were available for all 15 European Union countries and
for five of the 10 applicant states including the Czech and Slovak
Republics for which data were combined to give the necessary
time span of data for input into the statistical models (see below).
Only recent data were available, however, for Estonia, Latvia,
Lithuania and Slovenia. [More historical data for the three Baltic
states and Slovenia will become available shortly.] No data were
available for Cyprus. Population estimates in 5-year age groups
from the 1950s to 2000 for each country were also obtained from
the WHO database. Corresponding population projections up to
2020 were obtained from the United Nations database.
Mortality rates were modelled as a function of age, calendar
period and birth cohort. Birth cohort was calculated as age sub-
tracted from calendar period. Since the data were aggregated into
5-year age groups and 5-year calendar periods, the birth cohorts
are synthetic and partly overlapping
The general result from the forecasting of the future age specific
cancer mortality rates was that, in most countries, the age stand-
ardised rates are predicted to decrease; both the timing and the
extent of the decreases vary considerably among the countries.
Results for the individual cancer sites indicated that the overall
trends were largely dependent on the decreasing rates in lung
cancer mortality in males, and in breast cancer mortality in
females.
As a consequence of the generally decreasing trends in the
age standardised rates, the best estimate is that there will be ∼1.25
million cancer deaths in 2015, which is over 130000 (11%) more
deaths than in 2000, but 155000 (11%) fewer deaths than pro-
jected in 2015 on the basis of demographic changes alone. The
increases in the forecast numbers of cancer deaths in 2015 are
proportionally larger in males than in females (13% and 10%,
respectively) and proportionally larger in the applicant states than
in the current European Union member countries (14% and 11%,
respectively).
Future directions
A key element of the future will be the rapid emergence of new
technologies, some of which may have important impacts on
several aspects of cancer prevention, diagnosis and treatment.
Remarkable strides have been made in a number of technology
fields but their application to cancer medicine will take another
decade or so. It was thought to be of interest, nevertheless, to indi-
cate how new methodologies might begin to influence the areas of
cancer detailed in this code.
The most readily applicable new technologies are in imaging,
molecular typing of tissues and intelligent drug design.
It is possible that spiral CT examination of the lungs of smokers
might be shown to dramatically improve early detection of
resectable lung tumours. On the other hand it is quite unlikely that
sophisticated second generation nuclear magnetic resonance imag-
ing or positron emission tomography scanning will be routinely
applied to populations, even those at high risk. Rather they could
be useful in characterising suspicious lesions and of course in
delineating primary tumours and suspect metastases. Virtual
colonoscopy, on the other hand, may prove to be a valuable way to
screen for bowel cancer, as may stool examination, not for blood,
but for the presence of mutated genes in sloughed cells.
Unravelling the molecular constitution of tissues is already a
reality, though not in any routine application. Thus tumour cells in
small numbers can be arrayed by gene and protein chip tech-
nology to reveal a molecular signature, specific to that tumour.
Perturbed patterns of gene and protein expression have already
been used to reclassify tumours, and to correlate with eventual
prognosis. Certain drug treatments and radiation regimes have
been correctly predicted to be ineffective in the environment
of specific genetic mutations. And, of course, a couple of specific
examples exist where targeted therapeutics, antibodies (such as
trastuzumab against her2-neu moieties) and small molecules
(such as imatinib against bcr-abl kinases), have become effective
treatments. In these and some other instances, gene and protein
technology has been used to monitor treatment, providing extremely
precise molecular end points.
Molecular examination of normal cells in a cancer patient may
also give a guide to the metabolic fate of a range of medicines.
Using this information, a number of drugs may be discarded as
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inappropriate for that person. The era of truly tailor-made treat-
ment may not be far off.
The new technologies mentioned above may provide oppor-
tunities for development of new diagnostics, e.g. for virus-
associated malignancies; they may be helpful in the analysis of
large population-based sets of tissues and offer new insights into
mechanisms of interaction between environmental factors, e.g.
dietary components and genotype; and they may be helpful in
selection of high risk volunteers for specific tailored chemo-
prevention trials. All told, the future appears to be full of bright
promise in cancer control and the challenge is to fulfill that poten-
tial.
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